<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carbamazepine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carbamazepine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Carbamazepine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9198" href="/d/html/9198.html" rel="external">see "Carbamazepine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11711" href="/d/html/11711.html" rel="external">see "Carbamazepine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708660"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious dermatologic reactions and HLA-B*1502 allele:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome, have been reported during treatment with carbamazepine. These reactions are estimated to occur in 1 to 6 per 10,000 new users in countries with mainly Caucasian populations, but the risk in some Asian countries is estimated to be about 10 times higher. Studies in patients of Chinese ancestry have found a strong association between the risk of developing Stevens-Johnson syndrome/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA-B gene. HLA-B*1502 is found almost exclusively in patients with ancestry across broad areas of Asia. Patients with ancestry in genetically at-risk populations should be screened for the presence of HLA-B*1502 prior to initiating treatment with carbamazepine. Patients testing positive for the allele should not be treated with carbamazepine unless the benefit clearly outweighs the risk.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Aplastic anemia and agranulocytosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Aplastic anemia and agranulocytosis have been reported in association with the use of carbamazepine. Data from a population-based case-control study demonstrate that the risk of developing these reactions is 5 to 8 times greater than in the general population. However, the overall risk of these reactions in the untreated general population is low, approximately 6 patients per 1 million population per year for agranulocytosis and 2 patients per 1 million population per year for aplastic anemia.</p>
<p style="text-indent:-2em;margin-left:2em;">Although reports of transient or persistent decreased platelet or white blood cell counts (WBCs) are not uncommon in association with the use of carbamazepine, data are not available to accurately estimate their incidence or outcome. However, the vast majority of the cases of leukopenia have not progressed to the more serious conditions of aplastic anemia or agranulocytosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the very low incidence of agranulocytosis and aplastic anemia, the vast majority of minor hematological changes observed in monitoring of patients on carbamazepine are unlikely to signal the occurrence of either abnormality. Nonetheless, complete pretreatment hematological testing should be obtained as a baseline. If a patient in the course of treatment exhibits low or decreased white blood cell or platelet counts, the patient should be monitored closely. Discontinuation of the drug should be considered if any evidence of significant bone marrow depression develops.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F145588"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Carbatrol;</li>
<li>Epitol;</li>
<li>Equetro;</li>
<li>TEGretol;</li>
<li>TEGretol-XR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866195"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>DOM-CarBAMazepine;</li>
<li>PMS-CarBAMazepine;</li>
<li>PMS-CarBAMazepine CR;</li>
<li>PMS-CarBAMazepine-CR;</li>
<li>SANDOZ CarBAMazepine CR;</li>
<li>TARO-CarBAMazepine;</li>
<li>TEGretol;</li>
<li>TEGretol CR;</li>
<li>TEVA-Carbamazepine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051488"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Miscellaneous</span></li></ul></div>
<div class="block dop drugH1Div" id="F145612"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Prior to initiating carbamazepine therapy, test for <i>HLA-B*15:02</i> allele in patients with increased risk for this genetic variant (eg, Han Chinese, Thai, Malaysian, Indian, or Vietnamese descent); this is associated with a significantly increased risk of Stevens-Johnson syndrome and/or toxic epidermal necrolysis; do <b>NOT </b>initiate in patients with a positive result (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24597466','lexi-content-ref-23695185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24597466','lexi-content-ref-23695185'])">Ref</a></span>). Although testing recommendations are not well established, consider testing for <i>HLA-A*31:01</i> and <i>HLA-A*24:02</i> allele. These alleles are found in a broader range of ethnic groups and also increase the risk for hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23695185','lexi-content-ref-28476759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23695185','lexi-content-ref-28476759'])">Ref</a></span>). A negative genetic test does not entirely rule out the possibility of a hypersensitivity or cutaneous reaction, and patients should be monitored throughout therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33243222-cb08-4d46-b4f8-2d9c8a772e74">Seizure disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizure disorder: </b>Dosage must be adjusted according to patient's response and serum concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;6 years:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immediate-release formulations:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Tablets: Initial: 10 to 20 mg/kg/day in divided doses twice or 3 times daily; titrate at weekly intervals until optimal response; maintenance doses administered 3 or 4 times daily; maximum daily dose: 35 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Suspension: Initial: 10 to 20 mg/kg/day in divided doses 4 times daily; titrate at weekly intervals until optimal response; maintenance doses administered 3 or 4 times daily; maximum daily dose: 35 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 to 12 years:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immediate-release formulations:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Tablets: Initial: 100 mg twice daily, titrate by up to 100 mg/day at weekly intervals. Usual maintenance dose range: 400 to 800 mg/day in 3 to 4 divided doses. Maximum daily dose: 1,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Suspension: Initial: 50 mg 4 times daily, titrate by up to 100 mg/day at weekly intervals. Usual maintenance daily dose range: 400 to 800 mg/day in 3 to 4 divided doses. Maximum daily dose: 1,000 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Extended-release formulations</i>: Capsules, tablets: Initial: 100 mg twice daily, titrate by up to 100 mg/day at weekly intervals. Usual maintenance daily dose range: 400 to 800 mg/day in divided doses twice daily. Maximum daily dose: 1,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immediate-release</i>
<i>formulations:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Tablets: Initial: 200 mg twice daily, titrate by up to 200 mg/day increments at weekly intervals. Usual maintenance daily dose range: 800 to 1,200 mg/day in divided doses 3 or 4 times daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Suspension: Initial: 100 mg 4 times daily, titrate by up to 200 mg/day increments at weekly intervals. Usual maintenance daily dose range: 800 to 1,200 mg/day in divided doses 3 or 4 times daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Extended-release formulations</i>: Capsule, tablet: Initial: 200 mg twice daily, titrate by up to 200 mg/day increments at weekly intervals. Usual maintenance daily dose range: 800 to 1,200 mg/day in divided doses twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Maximum daily doses:</p>
<p style="text-indent:-2em;margin-left:12em;">Adolescents ≤15 years: 1,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:12em;">Adolescents &gt;15 years: 1,200 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Limited data available: Infants, Children, and Adolescents: Maintenance dose: Administer the same total daily dose as small, diluted doses administered more frequently than the oral; dilute the oral suspension with an equal volume of water; if defecation occurs within the first 2 hours, repeat the dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3334021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3334021'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing conversions:</b> Close monitoring and possible dosage adjustment may be necessary during any dosage form conversions due to pharmacokinetics differences amongst immediate-release dosage forms (ie, suspension formulation produces higher peak concentrations compared to the tablet) and between the immediate- and extended-release formulations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion from immediate-release solid dosage form to suspension:</i> Use the same daily dose and divide into 3 daily doses; monitor serum concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion from immediate-release tablets to extended-release formulations:</i> Use the same daily dose and divide into 2 daily doses; monitor serum concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Discontinuation of treatment for epilepsy is dependent on several factors to minimize chance of seizure relapse. Favorable factors include: Childhood onset, normal EEG at time of discontinuation, idiopathic generalized epilepsy, low seizure frequency before and during treatment, seizure type, normal neurologic exam, and normal intellectual development. Withdrawal of therapy is typically evaluated if patient has been seizure free for 2 years. Abrupt discontinuation is not recommended. Gradual tapers have ranged from 6 weeks to 9 months. The slow discontinuation should be tailored to the patient's preference and needs. Other considerations include the drug pharmacokinetic properties, dosage at the start of withdrawal, dosage forms, and need for follow-up serum concentration monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24099051','lexi-content-ref-15015901','lexi-content-ref-25922863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24099051','lexi-content-ref-15015901','lexi-content-ref-25922863'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083900"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider measuring serum 10,11-carbamazepine epoxide levels in instances where toxicity is suspected, but serum carbamazepine levels are within normal range. Based on experience in adult patients, serum 10,11-carbamazepine epoxide levels may be increased with moderate to severe kidney dysfunction; clearance of parent drug and the 10,11-carbamazepine epoxide metabolite are urine flow dependent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18509811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18509811'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to severe impairment:</i> Initial: No dosage adjustment necessary. Monitor closely and adjust dose based on clinical response, tolerability (eg, adverse drug reactions), and serum concentrations of carbamazepine and its active metabolite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24122696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24122696'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> There are no dosing adjustments in the manufacturer's labeling; based on pharmacokinetic profile of carbamazepine (ie, lipophilicity, high protein binding, minimal renal clearance), no dose adjustments to initial doses necessary; monitor closely and adjust dose based on clinical response, tolerability, and serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30259204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30259204'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Initial: There are no dosing adjustments in the manufacturer's labeling; based on pharmacokinetic profile of carbamazepine (ie, lipophilicity, high protein binding, minimal renal clearance), no dose adjustments to initial doses necessary; monitor closely and adjust dose based on clinical response, tolerability, and serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30259204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30259204'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Continuous renal replacement therapy (CRRT): </b>There are no pediatric-specific recommendations for dosing in patients receiving CRRT; based on adult experience, dose adjustments should be based on clinical response, tolerability, and serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27587068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27587068'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51083901"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. Use with caution in hepatic impairment and consider dose reduction; metabolized primarily in the liver.</p></div>
<div class="block doa drugH1Div" id="F145593"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9198" href="/d/html/9198.html" rel="external">see "Carbamazepine: Drug information"</a>)</p>
<p style="text-indent:0em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Prior to initiating carbamazepine therapy, test for <i>HLA-B*15:02</i> allele in patients with increased risk for this genetic variant (eg, Han Chinese, Thai, Malaysian, Indian, or Vietnamese descent); this is associated with a significantly increased risk of Stevens-Johnson syndrome and/or toxic epidermal necrolysis; do <b>NOT</b> initiate in patients with a positive result (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24597466','lexi-content-ref-23695185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24597466','lexi-content-ref-23695185'])">Ref</a></span>). Although testing recommendations are not well established, consider testing for <i>HLA-A*31:01</i> and <i>HLA-A*24:02</i> allele. These alleles are found in a broader range of ethnic groups and also increase the risk for hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23695185','lexi-content-ref-28476759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23695185','lexi-content-ref-28476759'])">Ref</a></span>). A negative genetic test does not entirely rule out the possibility of a hypersensitivity or cutaneous reaction, and patients should be monitored throughout therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing recommendations are expressed as the total daily dose (ie, per 24 hours) unless stated otherwise. Total daily oral dose is given in 2 to 4 divided doses per day depending on the type of preparation. Immediate release (suspension, tablet, chewable tablet) (usually dosed 2 to 4 times daily) and 12-hour ER (dosed twice daily) preparations are available.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11c41800-79f8-4d91-919d-f7f9587d8690">Bipolar disorder, hypomania and mild to moderate mania or episodes with mixed features and bipolar major depression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder, hypomania and mild to moderate mania or episodes with mixed features (alternative agent) and bipolar major depression (alternative agent)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26979387','lexi-content-ref-Bobo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26979387','lexi-content-ref-Bobo.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute treatment (monotherapy): Oral:</b> Initial: 100 to 400 mg/day in 2 to 4 divided doses based on chosen formulation; may increase dose based on response and tolerability in increments of 200 mg/day every 1 to 4 days; usual dose range: 600 mg/day to 1.2 g/day in 2 to 4 divided doses based on chosen formulation; maximum dose: 1.6 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.1','lexi-content-ref-19347775','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.1','lexi-content-ref-19347775','lexi-content-ref-manu.1'])">Ref</a></span>). Doses up to 1.8 g/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.1'])">Ref</a></span>). Also see “Dosing” above.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance (monotherapy) (off-label use): Oral:</b> Continue dose that was used to achieve control of the acute episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26523730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26523730'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="67e732c4-b7e3-4abd-be74-0e133a5b58d8">Focal onset seizures and generalized onset seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Focal (partial) onset seizures and generalized onset seizures (monotherapy or adjunctive therapy): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Avoid use in nonmotor (absence) seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial 2 to 3 mg/kg/day (100 to 200 mg/day) in 2 to 4 divided doses based on chosen formulation <b>or</b> up to 400 mg/day in 2 to 4 divided doses based on chosen formulation (according to manufacturer's labeling), which may not be as well tolerated; may gradually increase dose based on seizure control, tolerability, and serum concentrations every ≥5 days in increments of ≤200 mg/day to a usual maintenance dose of ~10 mg/kg/day (800 mg/day to 1.2 g/day) in 2 to 4 divided doses based on chosen formulation. Serum concentrations may decrease due to hepatic enzyme autoinduction and dose may need to be further increased after 2 to 3 months of treatment to 15 to 20 mg/kg/day in 2 to 4 divided doses based on chosen formulation; doses up to ~2 g/day may be needed in some patients for optimal effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schachter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schachter.1'])">Ref</a></span>). Also see “Dosing” above.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="393e56f7-bded-45b3-b486-3009d2e7543b">Neuropathic pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuropathic pain: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in trigeminal or glossopharyngeal neuralgia. May also be used in critically ill patients with neuropathic pain as a component of multimodal pain control (alternative agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15976235','lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15976235','lexi-content-ref-30113379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 200 to 400 mg/day in 2 to 4 divided doses based on chosen formulation, gradually increasing (eg, over several weeks) in increments of 200 mg/day as needed. Usual maintenance dose: 600 to 800 mg/day in 2 to 4 divided doses based on chosen formulation; maximum dose: 1.2 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ho.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ho.1','lexi-content-ref-manu.1'])">Ref</a></span>). Also see “Dosing” above.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy: </b>In chronic therapy, withdraw gradually over 2 to 6 months to minimize the potential of increased seizure frequency (in patients with epilepsy) and other withdrawal symptoms (eg, dysphoria, hallucinations, headache, insomnia, tremor) unless safety concerns require more rapid withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24387898','lexi-content-ref-1673736','lexi-content-ref-Schachter.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24387898','lexi-content-ref-1673736','lexi-content-ref-Schachter.2'])">Ref</a></span>). In patients discontinuing therapy for treatment of bipolar disorder, close monitoring for several weeks to months for reemergence of mania/hypomania is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Post.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Post.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990411"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note:</b> In moderate to severe kidney dysfunction, serum 10,11-carbamazepine epoxide levels may be increased. Consider measuring serum 10,11-carbamazepine epoxide levels in instances where toxicity is suspected, but serum carbamazepine levels are within normal range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18509811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18509811'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mild to severe impairment:</b> Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24122696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24122696'])">Ref</a></span>). Subsequent dose adjustments should be based on patient response, tolerability, and serum concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Initial: No dosage adjustment necessary. Dose may be administered without regard to timing of dialysis on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7449356','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7449356','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Subsequent dose adjustments should be based on patient response, tolerability, and serum concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30259204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30259204'])">Ref</a></span>). Subsequent dose adjustments should be based on patient response, tolerability, and serum concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27587068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27587068'])">Ref</a></span>). Subsequent dose adjustments should be based on patient response, tolerability, and serum concentrations.</p></div>
<div class="block doha drugH1Div" id="F50987676"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution and consider dose reduction; carbamazepine is metabolized primarily in the liver.</p></div>
<div class="block arsc drugH1Div" id="F56280401"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Blood dyscrasias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hematologic effects with carbamazepine can be divided into bone marrow suppressive and proliferative effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2089834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2089834'])">Ref</a></span>). Bone marrow suppression-related hematological effects present as anemia, <b>aplastic anemia</b>,<b> leukopenia</b>,<b> neutropenia</b>, or<b> thrombocytopenia</b>. Proliferative effects can cause <b>eosinophilia</b>,<b> leukocytosis</b>, lymphocytosis, or macrocytosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2089834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2089834'])">Ref</a></span>). True incidence of hematological effects associated with carbamazepine is not known but appears to be low overall. One study determined an incidence of 0.14% for severe neutropenia and 0.03% for thrombocytopenia (as combined treatment) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15052517']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15052517'])">Ref</a></span>). Most cases of aplastic anemia had confounding variables, such as coincidental disease or concurrent medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2089834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2089834'])">Ref</a></span>). Leukopenia often reverses, even with continued treatment; rarely persistent and if so, typically clinically insignificant. Thrombocytopenia is reversible with discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2089834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2089834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; hematologic effects may occur due to immune-mediated or toxic mechanisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2089834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2089834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied. Based on case reports: Agranulocytosis: 6 to 1,100 days (most cases within 4 months of initiation); aplastic anemia: 4 to &gt;1,500 days; thrombocytopenia: 6 to 300 days. Leukopenia generally develops more slowly, typically within the first 3 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2089834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2089834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>General:</p>
<p style="text-indent:-2em;margin-left:8em;">- Concurrent mediations with additive hematologic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2089834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2089834'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- First year of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2089834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2089834'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- History of adverse hematologic reaction to any drug</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Leukopenia/neutropenia:</p>
<p style="text-indent:-2em;margin-left:8em;">- Low-normal or below-normal baseline WBC and neutrophil counts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2089834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2089834'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiac effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carbamazepine has been reported to increase the risk of <b>heart failure</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12044369','lexi-content-ref-9733403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12044369','lexi-content-ref-9733403'])">Ref</a></span>). <b>Sinus</b>
<b>tachycardia</b> may occur, especially in younger patients without preexisting heart disease in the setting of overdose. Bradyarrhythmia or atrioventricular (AV) conduction delay may also occur, especially in older females with long-term therapy at therapeutic or modestly elevated doses; reversible with discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1728915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1728915'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Carbamazepine blocks sodium channels, causing QRS interval prolongation, predisposing patients to hypotension and ventricular arrhythmias. May also unmask latent AV conduction defect in older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1728915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1728915'])">Ref</a></span>). Additionally, carbamazepine may have negative chronotropic and dromotropic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2017974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2017974'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; acute in younger patients with supratherapeutic levels (tachyarrhythmia) and chronic in older patients (bradyarrhythmia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1728915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1728915'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting AV conduction delay (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1728915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1728915'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Predisposition to conduction abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1728915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1728915'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications with AV-blocking effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1728915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1728915'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older females on chronic therapy are at higher risk of bradyarrhythmia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1728915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1728915'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger patients with overdose are at higher risk of tachyarrhythmia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1728915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1728915'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carbamazepine is associated with transient, asymptomatic <b>increased serum transaminases</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684'])">Ref</a></span>); <b>increased gamma-glutamyl transferase </b>(GGT) levels and <b>increased serum alkaline phosphatase</b> (ALP) due to the enzyme-inducing properties of carbamazepine, rather than cell damage, have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29898616','lexi-content-ref-28974841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29898616','lexi-content-ref-28974841'])">Ref</a></span>). <b>Hepatotoxicity</b> (<b>hepatocellular hepatitis</b>, <b>cholestatic hepatitis</b> or <b>hepatitis [mixed]</b>) can occur, often as part of <b>drug rash eosinophilia with systemic symptoms</b> (DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24554914','lexi-content-ref-33539847']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24554914','lexi-content-ref-33539847'])">Ref</a></span>). <b>Intrahepatic cholestasis</b> (vanishing bile duct syndrome [also known as ductopenic syndrome]) and granulomatous hepatitis have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30926241','lexi-content-ref-7247130','lexi-content-ref-12352223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30926241','lexi-content-ref-7247130','lexi-content-ref-12352223'])">Ref</a></span>). Hepatotoxicity is generally reversible upon discontinuation of therapy, with improvements observed over a period of days and normalization of serum liver enzymes within 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29898616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29898616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; acute liver injury may be caused by immune-mediated mechanisms triggered by arene oxide metabolite formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24879980','lexi-content-ref-29898616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24879980','lexi-content-ref-29898616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; duration of therapy prior to hepatotoxicity usually ranges from 6 to 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24879980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24879980'])">Ref</a></span>); although can be several months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684','lexi-content-ref-24879980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684','lexi-content-ref-24879980'])">Ref</a></span>). Elevated liver enzyme tests most often occur within the first 2 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• HLA-A*3101 may increase susceptibility to hepatotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33222552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33222552'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy (median duration: 30 weeks) may be associated with a poor outcome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapy with other hepatotoxic drugs or drugs that increase carbamazepine levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29898616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29898616'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High degree of cross-reactivity exists between aromatic antiseizure medications, including phenytoin, carbamazepine, phenobarbital, primidone, and oxcarbazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24879980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24879980'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• An increased risk of severe injury has been noted in pediatric patients &lt;10 years of age with hepatocellular injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A variety of delayed hypersensitivity reactions, ranging from mild with <b>maculopapular rash </b>(also known as morbilliform rash) to severe cutaneous adverse reactions (SCARs), including <b>Stevens-Johnson syndrome/toxic epidermal necrolysis </b>(SJS/TEN),<b> drug reaction with eosinophilia and systemic symptoms </b>(DRESS)<b>,</b> and <b>acute generalized exanthematous pustulosis</b> (AGEP) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30951222','lexi-content-ref-33188522','lexi-content-ref-29027197','lexi-content-ref-29501520','lexi-content-ref-31332981','lexi-content-ref-22477826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30951222','lexi-content-ref-33188522','lexi-content-ref-29027197','lexi-content-ref-29501520','lexi-content-ref-31332981','lexi-content-ref-22477826'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Delayed hypersensitivity reactions, including maculopapular eruptions and SCARs are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied. Maculopapular rash usually occurs 3 to 20 days after start of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30955419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30955419'])">Ref</a></span>). SCARs usually occur 1 to 12 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23744424','lexi-content-ref-26120552','lexi-content-ref-NICE.1','lexi-content-ref-31562941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23744424','lexi-content-ref-26120552','lexi-content-ref-NICE.1','lexi-content-ref-31562941'])">Ref</a></span>); reexposure may lead to more rapid onset (usually with 1 to 4 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-27086495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-27086495'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• General:</p>
<p style="text-indent:-2em;margin-left:8em;">- HLA-A*3101 has been identified as potential risk factor for SJS/TEN, DRESS and maculopapular eruption induced by carbamazepine in European, Japanese, and Korean patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31899808','lexi-content-ref-29392710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31899808','lexi-content-ref-29392710'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- High degree of cross-reactivity exists between aromatic antiseizure medications, including phenytoin, carbamazepine, phenobarbital, primidone, and oxcarbazepine; lamotrigine may also show cross-sensitivity with carbamazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28256714','lexi-content-ref-29898616','lexi-content-ref-22794330','lexi-content-ref-22211830','lexi-content-ref-16096883','lexi-content-ref-20888266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28256714','lexi-content-ref-29898616','lexi-content-ref-22794330','lexi-content-ref-22211830','lexi-content-ref-16096883','lexi-content-ref-20888266'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Very young patients and older patients may be at risk for severe SCARs associated with aromatic antiseizure medications, including carbamazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30955419','lexi-content-ref-23744424','lexi-content-ref-22794330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30955419','lexi-content-ref-23744424','lexi-content-ref-22794330'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• DRESS:</p>
<p style="text-indent:0em;margin-left:6em;">- Family history of DRESS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25933949','lexi-content-ref-29898616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25933949','lexi-content-ref-29898616'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Viral reactivation, in particular human herpesvirus 6 (HHV-6) reactivation may be associated with a prolonged and more severe course of DRESS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28256714','lexi-content-ref-25369238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28256714','lexi-content-ref-25369238'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• SJS/TEN:</p>
<p style="text-indent:-2em;margin-left:8em;">- HLA-B*1502 allele increases risk of SJS/TEN in South-East Asian populations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31899808','lexi-content-ref-29392710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31899808','lexi-content-ref-29392710'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Cranial irradiation may increase the risk of SJS/TEN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11907855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11907855'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carbamazepine may cause syndrome of inappropriate antidiuretic hormone secretion (<b>SIADH</b>) and <b>hyponatremia</b>. Incidence varies from 1.8% to 40%. Most cases reported in the literature are asymptomatic or mild. It is also rare that carbamazepine monotherapy can contribute to clinically significant hyponatremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759','lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759','lexi-content-ref-16189283'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>
<i>:</i> Dose-related; carbamazepine may increase the sensitivity of osmoreceptors to ADH in the distal convoluted tubules and collecting ducts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; one case reported onset within 24 hours in the setting of high doses/serum drug concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16189283'])">Ref</a></span>). Another case reported onset within 2 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• High doses/serum drug concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759','lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759','lexi-content-ref-16189283'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759','lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759','lexi-content-ref-16189283'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;40 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759','lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759','lexi-content-ref-16189283'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low baseline serum sodium levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759','lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759','lexi-content-ref-16189283'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Psychiatric illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759','lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759','lexi-content-ref-16189283'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759','lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759','lexi-content-ref-16189283'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypothyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759','lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759','lexi-content-ref-16189283'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that cause SIADH (eg, selective serotonin reuptake inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759','lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759','lexi-content-ref-16189283'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31198759','lexi-content-ref-16189283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31198759','lexi-content-ref-16189283'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carbamazepine may cause CNS effects, such as <b>ataxia</b>, <b>dizziness</b>, and <b>drowsiness </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18698874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18698874'])">Ref</a></span>), as well as psychiatric effects such as <b>anxiety</b> and <b>depression</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8444328','lexi-content-ref-18698874','lexi-content-ref-2362393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8444328','lexi-content-ref-18698874','lexi-content-ref-2362393'])">Ref</a></span>). The depression risk with carbamazepine may be lower than other conventional antiseizure medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18698874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18698874'])">Ref</a></span>). Rare reports of <b>psychosis </b>have been associated with polydipsia after taking carbamazepine, which resolved following correction of hyponatremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18698874','lexi-content-ref-8991788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18698874','lexi-content-ref-8991788'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Hyponatremia may contribute to psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18698874','lexi-content-ref-8991788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18698874','lexi-content-ref-8991788'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses and concentrations of carbamazepine and its active metabolite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18698874','lexi-content-ref-Leach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18698874','lexi-content-ref-Leach.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation/tendencies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antiseizure medications have been associated with suicidal ideation and suicidal tendencies. However, the FDA meta-analysis has been criticized due to several important limitations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19496806','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19496806','lexi-content-ref-22994856'])">Ref</a></span>). The risk of suicide is increased in epilepsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19453718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19453718'])">Ref</a></span>), but the occurrence of suicidal ideation/tendencies in epilepsy is multifactorial. While some antiseizure medications (but not all) have been associated with treatment-emergent psychiatric effects such as anxiety and depression, other factors such as post-ictal suicidal behavior and pertinent patient history must also be evaluated to provide an accurate assessment of risk for any individual drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22994856'])">Ref</a></span>). Due to the tricyclic structure of carbamazepine, the depression risk may be lower than with other conventional antiseizure medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18698874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18698874'])">Ref</a></span>). Carbamazepine has been associated with a lower incidence of suicidal behavior compared to barbiturates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18698874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18698874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; peak incidence of suicidality across antiseizure medications (not specific to individual agents) has been noted to occur between 1 and 12 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254','lexi-content-ref-20388896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254','lexi-content-ref-20388896'])">Ref</a></span>). A review of clinical trials noted that risk extended from 1 week to 24 weeks of therapy, corresponding to the duration of most trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>History of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889','lexi-content-ref-18698874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889','lexi-content-ref-18698874'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use in conditions other than epilepsy or bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• In patients with bipolar disorder, risk for repeat suicide attempt was increased in patients with alcohol/substance abuse disorder, rapid cycling, and earlier age at onset of first manic episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F145551"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (29%), vomiting (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia (15%)<span class="lexi-table-link-container"> (<a aria-label="Ataxia table link" class="lexi-table-link" data-table-id="lexi-content-ataxia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ataxia')">table 1</a>)</span><span class="table-link" style="display:none;">Ataxia</span>, dizziness (44%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 2</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (32%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 3</a>)</span><span class="table-link" style="display:none;">Drowsiness</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ataxia" frame="border" id="lexi-content-ataxia" rules="all">
<caption style="text-align:center;">
<b>Carbamazepine: Adverse Reaction: Ataxia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Carbamazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carbamazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 1,600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acute mania associated with bipolar I disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">251</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">248</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Carbamazepine: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Carbamazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carbamazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 1,600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acute mania associated with bipolar I disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">251</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">248</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Carbamazepine: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Carbamazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carbamazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 1,600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acute mania associated with bipolar I disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">251</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">248</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (3%; including exacerbation of hypertension)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (8%), skin rash (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (10%), xerostomia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking (2%), asthenia (8%), paresthesia (2%), speech disturbance (6%), tremor (3%), twitching (2%), vertigo (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial insufficiency (cerebral artery), atrioventricular block (including second-degree atrioventricular block and complete atrioventricular block) (Koutsampasopoulos 2014), cardiac arrhythmia, collapse, coronary artery disease (aggravation), edema, heart failure, hypotension, pulmonary embolism, sinus tachycardia (Kasarskis 1992), syncope, thromboembolism, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Skalli 2011), alopecia (Ikeda 1997), diaphoresis, dyschromia, erythema multiforme (Upadhyaya 2012), erythema nodosum, erythematous rash, exfoliative dermatitis, maculopapular rash (Hadzić 1990), onychomadesis, pruritic rash, skin photosensitivity, Stevens-Johnson syndrome (Khoo 2016), toxic epidermal necrolysis (Stătescu 2017), urticaria, vitiligo (Assaedi 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acute intermittent porphyria (Yeung Laiwah 1983), albuminuria, decreased serum calcium, decreased thyroid hormones, hirsutism, hyperammonemia (Singh 2015), hyperlipidemia (Mintzer 2020), hyponatremia (Kaeley 2019), porphyria (variegate) (Grieco 2001), porphyria cutanea tarda (Leo 1996), SIADH (Kaeley 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, dysgeusia (Syed 2016), gastric distress, glossitis, glottis edema, pancreatitis (Ali 2021), stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Acute urinary retention (Hmouda 2007), azotemia, defective spermatogenesis, glycosuria, impotence, microscopic urine deposits, oliguria, reduced fertility (male), urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Adenopathy, agranulocytosis (Sobotka 1990), aplastic anemia (Sobotka 1990), bone marrow depression (Sobotka 1990), eosinophilia (Sobotka 1990), hypogammaglobulinemia, leukocytosis (Sobotka 1990), leukopenia (Sobotka 1990), lymphadenopathy (Hadzić 1990), neutropenia (Sobotka 1990), pancytopenia (Sobotka 1990), purpuric disease, thrombocytopenia (Sobotka 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Ganesh 2017), granulomatous hepatitis (Hadzić 1990), hepatic failure (Hadzić 1990), hepatitis (mixed), hepatocellular hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2021), increased gamma-glutamyl transferase (Hadzagic-Catibusic 2017), increased serum alkaline phosphatase (Hadzagic-Catibusic 2017), increased serum transaminases, intrahepatic cholestasis (vanishing bile duct syndrome), jaundice (Hadzić 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Subramanian 2016), drug reaction with eosinophilia and systemic symptoms (Chung 2021), lip edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety (Kennedy 2008), aseptic meningitis (Dang 1996), asterixis (Singh 2015), chills, confusion, depression (Kennedy 2008), fatigue, headache, hyperacusis, involuntary body movements, neuroleptic malignant syndrome (O’Griofa 1991), peripheral neuritis, psychosis (Kennedy 2008), talkativeness, unsteadiness, visual hallucination</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (Hadzić 1990), exacerbation of systemic lupus erythematosus, lower limb cramp, lupus-like syndrome (Kanno 1992, Reiffers-Mettelock 1997), myalgia, osteoporosis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, diplopia, eye movement disorder, eyelid edema, increased intraocular pressure (Atalay 2014), nystagmus disorder (Fohlen 2022), punctate cataract</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Jubert 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry throat, laryngeal edema, pulmonary hypersensitivity reaction (Cullinan 1975)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Hadzić 1990)</p></div>
<div class="block coi drugH1Div" id="F145567"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to carbamazepine, tricyclic antidepressants, or any component of the formulation; bone marrow depression; with or within 14 days of MAO inhibitor use; concomitant use of nefazodone, delavirdine, or other non-nucleoside reverse transcriptase inhibitors that are substrate of CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Atrioventricular (AV) heart block; hepatic disease; history of hepatic porphyria (acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda); serious blood disorder; concurrent use with itraconazole and voriconazole.</p></div>
<div class="block war drugH1Div" id="F145548"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias: <b>[US Boxed Warning]: The risk of developing anemia or agranulocytosis is increased during treatment. Complete pretreatment hematological testing should be obtained prior to use; monitor patient closely if white blood cells or platelet counts decrease during therapy; discontinue if significant bone marrow suppression occurs.</b> A spectrum of hematologic effects has been reported with use (eg, agranulocytosis, aplastic anemia, neutropenia, leukopenia, thrombocytopenia, pancytopenia, and anemias); patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, and petechial or purpuric hemorrhage.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: <b>[US Boxed Warning]: Severe and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), may occur during therapy. The risk is increased in patients with the variant HLA-B*1502 allele, found most often in patients of Asian ancestry. Patients with an increased likelihood of carrying this allele should be screened prior to initiating therapy. Avoid use in patients testing positive for the allele; discontinue therapy in patients who have a serious dermatologic reaction.</b> The risk of SJS or TEN may also be increased if carbamazepine is used in combination with other antiseizure drugs associated with these reactions. Presence of the <i>HLA-B*1502</i> allele has not been found to predict the risk of less serious dermatologic reactions such as antiseizure hypersensitivity syndrome or nonserious rash.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatotoxicity ranging from slight elevations in liver enzymes to rare hepatic failure has been reported and may occur concomitantly with other immunoallergenic syndromes such as multiorgan hypersensitivity (DRESS syndrome) and serious dermatologic reactions including SJS; monitor baseline and periodic liver function, particularly in patients with a history of liver disease; discontinue carbamazepine immediately in cases of aggravated liver dysfunction or active liver disease. In some cases, hepatic effects may progress despite discontinuation of carbamazepine. Rare cases of a hepatic failure and vanishing bile duct syndrome involving destruction and disappearance of the intrahepatic bile ducts have been reported. Clinical courses of vanishing bile duct syndrome have been variable ranging from fulminant to indolent.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: The risk of developing a hypersensitivity reaction may be increased in patients with the variant <i>HLA-A*3101</i> allele. These hypersensitivity reactions include SJS/TEN, maculopapular eruptions, and drug reaction with eosinophilia and systemic symptoms (DRESS/multiorgan hypersensitivity). The <i>HLA-A*3101</i> allele may occur more frequently in patients of African-American, Asian, European, Indian, Arabic, Latin American, and Native American ancestry. Hypersensitivity has also been reported in patients experiencing reactions to other antiseizure medications; the history of hypersensitivity reactions in the patient or their immediate family members should be reviewed. Approximately 25% to 30% of patients allergic to carbamazepine will also have reactions with oxcarbazepine. Also, rare cases of anaphylaxis and angioedema have been reported; may occur after first dose or subsequent doses. Discontinue therapy if symptoms occur. Do not rechallenge patients if such reactions occur; initiate alternative treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyponatremia: Hyponatremia may occur and is often caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Risk of SIADH appears to be dose-related. Elderly or patients taking diuretics are at increased risk for hyponatremia. Consider discontinuing therapy in patients with symptomatic hyponatremia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiorgan hypersensitivity reactions: Potentially serious, sometimes fatal multiorgan hypersensitivity reactions (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]) have been reported with some antiseizure drugs; including carbamazepine; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; gradual discontinuation and conversion to alternate therapy may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric effects: May activate latent psychosis and/or cause confusion or agitation; elderly patients may be at an increased risk for psychiatric effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Renal toxicity has been reported; monitor renal function at baseline and periodically thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: Pooled analysis of trials involving various antiseizure medications (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticholinergic sensitivity: Has mild anticholinergic activity; use with caution in patients with sensitivity to anticholinergic effects (urinary retention, increased intraocular pressure, constipation).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: May cause conduction abnormalities, including AV heart block; use caution in patients with underlying ECG abnormalities, preexisting cardiac damage, or patients who are at risk for conduction abnormalities. In a scientific statement from the American Heart Association, carbamazepine has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) in patients with heart failure (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; avoid use in patients with hepatic porphyria (eg, acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition (Mehrizi 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asian ancestry: <b>[US Boxed Warning]: Patients with an increased likelihood of carrying the HLA-B*1502 allele,</b> such as those of Asian descent<b>, should be screened for the variant HLA-B*1502 allele prior to initiating therapy. This genetic variant has been associated with a significantly increased risk of developing Stevens-Johnson syndrome and/or toxic epidermal necrolysis. Patients with a positive result should not be started on carbamazepine.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: May activate latent psychosis, confusion, or agitation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Exacerbation of certain seizure types have been seen after initiation of therapy in children with mixed seizure disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sorbitol: The suspension may contain sorbitol; avoid use in patents with hereditary fructose intolerance.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suspension: Administration of the suspension will yield higher peak and lower trough serum levels than an equal dose of the tablet form; consider a lower starting dose given more frequently (same total daily dose) when using the suspension.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not effective in absence, myoclonic, or akinetic seizures; carbamazepine administration may increase the frequency of seizures in patients with these types of seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878365"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Substitution of different carbamazepine products may result in changes in serum concentrations; closely monitor serum concentrations when a change in product is required.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F145559"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 12 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carbatrol: 100 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carbatrol: 200 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Equetro: 100 mg, 200 mg, 300 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TEGretol: 100 mg/5 mL (450 mL) [contains fd&amp;c yellow #6 (sunset yellow), propylene glycol; citrus-vanilla flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL, 10 mL, 450 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epitol: 200 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TEGretol: 200 mg [scored; contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TEGretol-XR: 100 mg, 200 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg, 400 mg</p></div>
<div class="block geq drugH1Div" id="F145544"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F145570"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, 12-hour</b> (carBAMazepine ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.91 - $1.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1.91 - $1.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $1.91 - $1.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, 12-hour</b> (Carbatrol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $2.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, 12-hour</b> (Equetro Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $4.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $5.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $5.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (carBAMazepine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.64 - $0.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (carBAMazepine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $0.17 - $1.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (TEGretol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $0.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (carBAMazepine ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.10 - $1.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1.61 - $2.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $3.23 - $4.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (TEGretol-XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $3.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $7.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (carBAMazepine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1.12 - $1.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Epitol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (TEGretol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $3.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866196"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TEGretol: 100 mg/5 mL (450 mL) [contains fd&amp;c yellow #6 (sunset yellow), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (450 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TEGretol: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TEGretol CR: 200 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg, 400 mg</p></div>
<div class="block exp drugH1Div" id="F10806347"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Commercial oral suspension is available (20 mg/mL)</p>
<p style="text-indent:0em;">
<b>40 mg/mL Oral Suspension</b></p>
<p style="text-indent:0em;margin-top:2em;">A 40 mg/mL oral suspension may be made with tablets. Crush twenty 200 mg tablets in a mortar and reduce to a fine powder. Add small portions of Simple Syrup, NF and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 100 mL. Label "shake well" and "refrigerate". Stable for 90 days.</p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52612363"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Chewable and conventional tablets: Administer with food 2 to 3 times daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral suspension: Shake well before use; administer with food 3 to 4 times daily. Since a dose of suspension will produce higher peak and lower trough levels than the same dose given as the tablet form, patients given the suspension should be started on lower doses given more frequently (same total daily dose) and increased slowly to avoid unwanted side effects. When carbamazepine suspension has been combined with chlorpromazine or thioridazine solutions, a precipitate forms which may result in loss of effect. Therefore, it is recommended that the carbamazepine suspension dosage form not be administered at the same time with other liquid medicinal agents or diluents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Capsules (Carbatrol, Equetro): Consists of 3 different types of beads: Immediate release, extended release, and enteric release. The bead types are combined in a ratio to allow twice daily dosing. Capsules may be opened and contents sprinkled over food such as a teaspoon of applesauce; do not store medication/food mixture for later use; drink fluids after dose to make sure mixture is completely swallowed; may be administered with or without food; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet (Tegretol-XR): Administer with food twice daily; examine XR tablets for cracks or chips or other damage; do not use damaged extended-release tablets without release portal. Swallow tablet whole; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Dilute the oral suspension with an equal volume of water prior to administer; if defecation occurs within the first 2 hours, repeat the dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3334021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3334021'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F145564"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Chewable or IR tablets: Administer with food.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Shake well before administration. Must be given on a 3 to 4 times/day schedule versus tablets, which can be given 2 to 4 times/day. Because a given dose of suspension will produce higher peak and lower trough levels than the same dose given as the tablet form, patients given the suspension should be started on lower doses given more frequently (same total daily dose) and increased slowly to avoid unwanted side effects. When carbamazepine suspension has been combined with chlorpromazine or thioridazine solutions, a precipitate forms, which may result in loss of effect. Therefore, it is recommended that the carbamazepine suspension dosage form not be administered at the same time with other liquid medicinal agents or diluents. Should be administered with meals.</p>
<p style="text-indent:-2em;margin-left:4em;">ER capsule (Carbatrol, Equetro): Consists of three different types of beads: immediate release, extended release, and enteric release. The bead types are combined in a ratio to allow twice daily dosing. May be opened and contents sprinkled over food such as a teaspoon of applesauce; may be administered with or without food; do not crush or chew capsule or beads inside capsule.</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: Should be inspected for damage. Damaged ER tablets (without release portal) should not be administered. Should be administered with meals; swallow whole, do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Capsule and tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Do not cut, crush, or chew. Switch to IR formulation (tablet, chewable tablet, or oral suspension).</p></div>
<div class="block hazard drugH1Div" id="F49130943"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F15678960"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Carbatrol, Equetro: Store at controlled room temperature (25°C [77°F]); excursions permitted to 15°C to 30°C (59°F to 86°F); protect from light and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Tegretol-XR: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); protect from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Tegretol tablets and chewable tablets: Store at ≤30°C (86°F); protect from light and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Tegretol suspension: Store at ≤30°C (86°F); shake well before using.</p></div>
<div class="block meg drugH1Div" id="F10968527"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Carbatrol: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F020712s038lbl.pdf%23page%3D23&amp;token=ISShl%2BQ%2FBbu%2BCUivVqr3tD6KJtpgyYag0bSKdo4V1VCMoRL5O6BJt2X%2F16t4ChN9HeG%2FbHrdi0DtVlBW25d81ZFvzMokdXFwcqFUHbCYB3MmxjB4w%2Fg%2F8DWuDFTUl3vo&amp;TOPIC_ID=13113" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020712s038lbl.pdf#page=23</a></p>
<p style="text-indent:-2em;margin-left:4em;">Equetro: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F021710s018lbl.pdf%23page%3D27&amp;token=yaFuz%2BiFsE1r0sscVlHq%2BJ5xUqCm0jXnRG%2FGb5cuuDL7luPBe1HagiEuRBpkQLIV9O%2BmCsCf4FmxPDNHfE9BX8wSMx7qd7zJMt8HA7W68P%2BYsUUWIuEjeI8AvL4fR0%2BE&amp;TOPIC_ID=13113" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021710s018lbl.pdf#page=27</a></p>
<p style="text-indent:-2em;margin-left:4em;">TEGretol, TEGretol-XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F016608s121_018927s60_020234s054lbl.pdf%23page%3D19&amp;token=7XkWCpoCtwJ1BWNpGQV5hAxg%2BvnoAoolwUXXxvPm8z4soPTVy44fSs22OL8%2FWteQeCeigRKjK34P0mhoAd97pnv1xSWIlhP%2Fy1gVS%2BeYTtRkg51MtsUHEviUQPsEPa0WlDzcYvOUkQ2ZL7QqkrKZ5g%3D%3D&amp;TOPIC_ID=13113" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/016608s121_018927s60_020234s054lbl.pdf#page=19</a></p></div>
<div class="block usep drugH1Div" id="F53565862"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of generalized tonic-clonic, partial (especially complex partial), and mixed partial or generalized seizure disorder (Carbatrol, Epitol, Equetro, Tegretol: FDA approved in pediatric patients [age not specified] and adults; Tegretol-XR: FDA approved in ages ≥6 years and adults); relief of pain in trigeminal neuralgia or glossopharyngeal neuralgia (Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR: FDA approved in adults); treatment of bipolar I disorders with acute mania and mixed features (Equetro: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F145644"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CarBAMazepine may be confused with OXcarbazepine</p>
<p style="text-indent:-2em;margin-left:4em;">Epitol may be confused with Epinal</p>
<p style="text-indent:-2em;margin-left:4em;">Tegretol, Tegretol-XR may be confused with Toprol-XL, Toradol, Trental</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Carbamazepine is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F145630"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> BCRP/ABCG2, CYP1A2 (weak), CYP2B6 (moderate), CYP2C9 (weak), CYP3A4 (strong), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1, UGT1A1</p></div>
<div class="block dri drugH1Div" id="F145553"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abiraterone Acetate.  Management: Avoid when possible. If the combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during combined use. Reduce abiraterone dose back to the prior dose and frequency once strong inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Acalabrutinib.  Management: Avoid co-administration of strong CYP3A inducers in patients taking acalabrutinib. If strong CYP3A inducers cannot be avoided, increase the dose of acalabrutinib to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: CarBAMazepine may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Adagrasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adenosine: CarBAMazepine may enhance the adverse/toxic effect of Adenosine. Specifically, the risk of higher degree heart block may be increased.  Management: Monitor for increased degrees of heart block and bradycardia when these agents are combined. Consider using a lower initial dose of adenosine (3 mg) for the treatment of supraventricular tachycardia in patients who are receiving carbamazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.  Management: Increase the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-gp inducers with afatinib. Reduce afatinib dose back to the original afatinib dose 2 to 3 days after discontinuation of the P-gp inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Albendazole: CarBAMazepine may decrease serum concentrations of the active metabolite(s) of Albendazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfacalcidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alfacalcidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and strong CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: May increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alpelisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Amiodarone. CYP3A4 Inducers (Strong) may decrease the serum concentration of Amiodarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Strong) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Apixaban. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of ARIPiprazole.  Management: For indications other than major depressive disorder: double the oral aripiprazole dose over 1 to 2 weeks and closely monitor. Avoid use of strong CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Patients taking the 441 mg dose of aripiprazole lauroxil increase their dose to 662 mg if used with a strong CYP3A4 inducer for more than 14 days. No dose adjustment is necessary for patients using the higher doses of aripiprazole lauroxil.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Armodafinil: CarBAMazepine may decrease the serum concentration of Armodafinil. Armodafinil may decrease the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artesunate: CarBAMazepine may decrease serum concentrations of the active metabolite(s) of Artesunate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: CarBAMazepine may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of CarBAMazepine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CarBAMazepine may decrease the serum concentration of Avacopan. Avacopan may increase the serum concentration of CarBAMazepine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bazedoxifene: CarBAMazepine may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or, if bazedoxifene is combined with estrogen therapy, an increased risk of endometrial hyperplasia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Belumosudil.  Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Berotralstat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Betamethasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: CarBAMazepine may decrease the serum concentration of Bictegravir.  Management: When possible consider using an alternative antiseizure drug with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisoprolol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bisoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brexpiprazole.  Management: If brexpiprazole is used together with a strong CYP3A4 inducer, the brexpiprazole dose should gradually be doubled over the course of 1 to 2 weeks. Decrease brexpiprazole to original dose over 1 to 2 weeks if the strong CYP3A4 inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: May increase serum concentrations of the active metabolite(s) of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Brivaracetam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bromocriptine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bromperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brotizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brotizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: CYP2B6 Inducers (Moderate) may decrease the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Strong) may decrease the serum concentration of BusPIRone.  Management: Consider alternatives to this combination. If coadministration of these agents is deemed necessary, monitor patients for reduced buspirone effects and increase buspirone doses as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Butorphanol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Butorphanol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabazitaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabazitaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: UGT1A1 Inducers may decrease the serum concentration of Cabotegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.  Management: Avoid use of strong CYP3A4 inducers with cabozantinib if possible. If combined, increase cabozantinib capsules (Cometriq) by 40 mg from previous dose, max 180 mg daily. Increase cabozantinib tablets (Cabometyx) by 20 mg from previous dose, max 80 mg daily<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcifediol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers (Nondihydropyridine): May increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Management: Consider alternatives to this combination when possible. If combined, monitor for increased carbamazepine concentrations and toxicities and monitor for decreased calcium channel blocker efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Cannabidiol. CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cenobamate: May decrease the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ceritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: CarBAMazepine may decrease the serum concentration of Chlormethiazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproPAMIDE: CYP3A4 Inducers (Strong) may decrease the serum concentration of ChlorproPAMIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cilnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: CYP3A4 Inducers (Strong) may decrease the serum concentration of Citalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CarBAMazepine may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Clarithromycin.  Management: Consider alternatives to this combination when possible. If combined, monitor for increased carbamazepine effects/toxicities and for reduced clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CarBAMazepine may decrease the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClonazePAM: CYP3A4 Inducers (Strong) may decrease the serum concentration of ClonazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CarBAMazepine may enhance the myelosuppressive effect of CloZAPine. More specifically, the risk of bone marrow suppression with this combination may be increased due to the independent myelosuppressive effects of the drugs. CarBAMazepine may decrease the serum concentration of CloZAPine.  Management: Avoid use with strong CYP3A4 inducers when possible. If combined, monitor patients closely and consider clozapine dose increases. Consider increased monitoring for neutropenia<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: CarBAMazepine may decrease the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of CarBAMazepine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cola-Containing Drinks: May increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Colchicine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Copanlisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: CYP2B6 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of CycloPHOSphamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Monitor closely for reduced cyclosporine concentrations when combined with strong CYP3A4 inducers. Cyclosporine dose increases will likely be required to maintain adequate serum concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Weak): May decrease the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of CarBAMazepine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Weak): May increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cyproterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with P-glycoprotein inducers whenever possible.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daclatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): May enhance the adverse/toxic effect of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Darolutamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid concurrent use of dasatinib with strong CYP3A4 inducers when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: UGT1A1 Inducers may decrease the serum concentration of Deferasirox.  Management: Avoid concomitant use of deferasirox and UGT1A1 inducers when possible. If combined, consider a 50% increase in the initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical response to guide further dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Delamanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: CarBAMazepine may decrease the serum concentration of Delavirdine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of DexAMETHasone (Systemic).  Management: Consider dexamethasone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced dexamethasone efficacy. Consider avoiding this combination when treating life threatening conditions (ie, multiple myeloma).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inducers (Strong) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: CarBAMazepine may decrease the serum concentration of Dolutegravir.  Management: Increase dolutegravir to 50 mg twice/day in adults. Increase weight-based dose to twice daily in pediatric patients. Specific recommendations vary for combination products; see interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Domperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Doravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: CarBAMazepine may decrease the serum concentration of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Duvelisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ebastine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Edoxaban.  Management: Avoid coadministration of edoxaban and P-glycoprotein (P-gp) inducers if possible. If concomitant use is required, be aware the edoxaban efficacy may be decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: CarBAMazepine may decrease the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of CarBAMazepine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elagolix. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix, Estradiol, and Norethindrone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elagolix, Estradiol, and Norethindrone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: CarBAMazepine may decrease the serum concentration of Elvitegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Encorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enfortumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Enzalutamide. CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.  Management: Consider using an alternative agent that has no or minimal CYP3A4 induction potential when possible. If this combination cannot be avoided, increase the dose of enzalutamide from 160 mg daily to 240 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eravacycline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eravacycline.  Management: Increase the eravacycline dose to 1.5 mg/kg every 12 hours when combined with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erdafitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.  Management: Avoid the combination of erlotinib and strong CYP3A4 inducers whenever possible. If this combination must be used, increase erlotinib dose by 50 mg increments every 2 weeks as tolerated, to a maximum of 450 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: CYP3A4 Inducers (Strong) may decrease the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eslicarbazepine: CarBAMazepine may enhance the adverse/toxic effect of Eslicarbazepine. CarBAMazepine may decrease the serum concentration of Eslicarbazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Estazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Strong) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethosuximide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ethosuximide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide. If combined, monitor patients closely for diminished etoposide response and need for etoposide dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide Phosphate.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide phosphate. If these combinations cannot be avoided, monitor patients closely for diminished etoposide phosphate response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoricoxib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoricoxib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Everolimus.  Management: Afinitor: Double the everolimus daily dose, using increments of 5 mg or less, with careful monitoring; multiple increments may be necessary. Zortress: Avoid if possible and monitor for decreased everolimus concentrations if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Evogliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Increase the exemestane dose to 50 mg once daily in patients receiving concurrent strong CYP3A4 inducers. Monitor patients closely for evidence of toxicity or inadequate clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ezogabine: CarBAMazepine may decrease the serum concentration of Ezogabine.  Management: Consider increasing the ezogabine dose when adding carbamazepine.  Monitor patients using the combination closely for evidence of adequate ezogabine therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fedratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felbamate: May increase serum concentrations of the active metabolite(s) of CarBAMazepine. Specifically, concentrations of the carbamazepine epoxide metabolite may be increased. CarBAMazepine may decrease the serum concentration of Felbamate. Felbamate may decrease the serum concentration of CarBAMazepine. Management: Initiate felbamate at typical doses (1,200 mg/day in 3 or 4 divided doses for adults and children 14 years of age or older; 15 mg/kg/day in 3 or 4 divided doses in children 2 to 14 years of age) while reducing the carbamazepine dose by 20%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Felodipine.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced felodipine efficacy and the need for felodipine dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fenfluramine.  Management: Avoid concurrent use of strong CYP3A4 inducers with fenfluramine when possible. If combined use cannot be avoided, consider increasing the fenfluramine dose, but do not exceed the fenfluramine maximum daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexofenadine: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Fexofenadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: CarBAMazepine may decrease the serum concentration of Fingolimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CarBAMazepine may decrease the serum concentration of Flunarizine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FLUoxetine: May increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Fosphenytoin-Phenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostemsavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fruquintinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Futibatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and strong CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse reactions, increase the gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers; resume 250 mg dose 7 days after discontinuation of the strong inducer. Carefully monitor clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Gemigliptin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gepirone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gestrinone: CarBAMazepine may decrease the serum concentration of Gestrinone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Gilteritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Glasdegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: CarBAMazepine may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CarBAMazepine may decrease the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Strong) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a strong CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Idelalisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid use of imatinib and strong CYP3A4 inducers when possible. If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely. Doses up to 1200 mg/day (600 mg twice daily) have been used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Indinavir.  Management: Consider avoiding the combination of indinavir and strong CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan Products.  Management: Avoid administration of strong CYP3A4 inducers during irinotecan treatment, and substitute non-CYP3A4 inducing agents at least 2 weeks prior to irinotecan initiation, whenever possible. If combined, monitor for reduced irinotecan efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Strong) may decrease isavuconazole serum concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: CarBAMazepine may enhance the hepatotoxic effect of Isoniazid. Isoniazid may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Istradefylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivosidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible. If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixazomib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Ketoconazole (Systemic).  Management: The use of ketoconazole concurrently with or within 2 weeks of a strong CYP3A4 inducer is not recommended. If such a combination cannot be avoided, monitor patients closely for evidence of diminished clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lacidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Antiseizure Agents (Sodium Channel Blockers) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: CarBAMazepine may enhance the adverse/toxic effect of LamoTRIgine. Specifically, the risk for hematologic toxicities may be increased. CarBAMazepine may enhance the arrhythmogenic effect of LamoTRIgine. CarBAMazepine may decrease the serum concentration of LamoTRIgine.  Management: Consider the risk of serious arrhythmias or death versus benefit of this combination. For patients taking carbamazepine without valproate, lamotrigine dose adjustments are recommended for lamotrigine initiation. See full interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If concomitant use cannot be avoided, titrate lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Larotrectinib.  Management: Avoid use of strong CYP3A4 inducers with larotrectinib. If this combination cannot be avoided, double the larotrectinib dose. Reduced to previous dose after stopping the inducer after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with P-glycoprotein/ABCB1 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin intravenous infusion with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with P-glycoprotein/ABCB1 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: UGT1A1 Inducers may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leuprolide and Norethindrone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Leuprolide and Norethindrone. Specifically, norethindrone concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: May enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonorgestrel (IUD): CYP3A4 Inducers (Strong) may diminish the therapeutic effect of Levonorgestrel (IUD). CYP3A4 Inducers (Strong) may decrease the serum concentration of Levonorgestrel (IUD). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Strong) may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: CarBAMazepine may enhance the adverse/toxic effect of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: CarBAMazepine may decrease the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of CarBAMazepine.  Management: Do not use a once daily lopinavir/ritonavir regimen together with carbamazepine. If used with a twice daily lopinavir/ritonavir regimen, monitor for reduced lopinavir/ritonavir effectiveness. Also monitor for increased carbamazepine effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Strong) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Lorlatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: May increase serum concentrations of the active metabolite(s) of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumacaftor and Ivacaftor. Specifically, the serum concentration of ivacaftor may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurbinectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inducers. If combined, monitor closely for decreased manidipine effects and loss of efficacy. Increased manidipine doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: CarBAMazepine may decrease the serum concentration of Maribavir.  Management: Increase the dose of maribavir to 800 mg twice daily when combined with carbamazepine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mebendazole: CarBAMazepine may decrease the serum concentration of Mebendazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Mefloquine. Mefloquine may decrease the serum concentration of CarBAMazepine. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If carbamazepine is being used for another indication, monitor for decreased concentrations and efficacy of both carbamazepine and mefloquine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylergonovine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Methylergonovine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Mianserin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midostaurin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirodenafil.  Management: Consider avoiding the concomitant use of mirodenafil and strong CYP3A4 inducers. If combined, monitor for decreased mirodenafil effects. Mirodenafil dose increases may be required to achieve desired effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirtazapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mitapivat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: CarBAMazepine may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.  Management: Do not use carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naldemedine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nateglinide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nateglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May increase the serum concentration of CarBAMazepine. Also, concentrations of the active CarBAMazepine epoxide metabolite may be reduced. CarBAMazepine may decrease the serum concentration of Nefazodone. Concentrations of active Nefazodone metabolites may also be reduced.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Netupitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): CarBAMazepine may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: CarBAMazepine may decrease the serum concentration of Nevirapine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiCARdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiCARdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Avoid coadministration of nifedipine with strong CYP3A4 inducers when possible and if combined, monitor patients closely for clinical signs of diminished nifedipine response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Nintedanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Nirmatrelvir and Ritonavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrazepam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nitrazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CarBAMazepine may decrease the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: CarBAMazepine may decrease the serum concentration of Omeprazole. Omeprazole may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ondansetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osilodrostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osimertinib.  Management: Avoid coadministration of osimertinib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase osimertinib to 160 mg daily. Reduce osimertinib to 80 mg daily 3 weeks after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: CYP3A4 Inducers (Strong) may decrease the serum concentration of OXcarbazepine. Specifically, the concentrations of the 10-monohydroxy active metabolite of oxcarbazepine may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Strong) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Paliperidone.  Management: Monitor for reduced paliperidone effects when combined with strong inducers of both CYP3A4 and P-gp. Avoid use of these inducers with extended-release injectable paliperidone and instead manage patients with paliperidone extended-release tablets.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used  with strong CYP3A4 inducers. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pexidartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pirtobrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pitolisant.  Management: If on a stable pitolisant dose of 8.9 mg or 17.8 mg/day and starting a strong CYP3A4 inducer, double the pitolisant dose over 7 days (ie, to either 17.8 mg/day or 35.6 mg/day, respectively). Reduce pitolisant dose by 50% when the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polatuzumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.  Management: Avoid coadministration of ponatinib with strong CYP3A4 inducers unless the potential benefit of concomitant treatment outweighs the risk of reduced ponatinib exposure. Monitor patients for reduced ponatinib efficacy if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: UGT1A1 Inducers may decrease the serum concentration of Ponesimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pralsetinib.  Management: Avoid concomitant use of pralsetinib with strong CYP3A4 inducers when possible. If combined, increase the starting dose of pralsetinib to double the current pralsetinib dosage starting on day 7 of coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pravastatin: CarBAMazepine may decrease the serum concentration of Pravastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: CarBAMazepine may increase the metabolism of Propacetamol. This may 1) diminish the desired effects of propacetamol; and 2) increase the risk of liver damage. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: May increase serum concentrations of the active metabolite(s) of CarBAMazepine. CarBAMazepine may decrease the serum concentration of QUEtiapine. Management: Quetiapine dose increases to as much as 5 times the regular dose may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7 to 14 days of discontinuing carbamazepine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CarBAMazepine may decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine.  Management: Consider alternatives to this combination when possible. If coadministration of carbamazepine and quinine cannot be avoided, monitor for reduced quinine efficacy and for increased carbamazepine serum concentrations and toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Radotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Radotinib.  Management: Consider alternatives to this combination when possible as the risk of radotinib treatment failure may be increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Reboxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Relugolix.  Management: Avoid use of relugolix with drugs that are both strong CYP3A4 and  P-glycoprotein (P-gp) inducer. If combined, increase the dose of relugolix to 240 mg once daily. Reduce back to 120 mg daily once the combined inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Relugolix, Estradiol, and Norethindrone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: CarBAMazepine may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ripretinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Strong) may decrease the serum concentration of RisperiDONE.  Management: Careful monitoring for reduced risperidone efficacy and possible dose adjustment are recommended when combined with strong CYP3A4 inducers. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: CarBAMazepine may decrease the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of CarBAMazepine.  Management: Consider avoiding this combination due to the potential for decreased ritonavir concentrations and the possible development of resistance. If combined, monitor for increased carbamazepine concentrations and effects and decreased ritonavir effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Rivaroxaban. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rolapitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: CarBAMazepine may decrease the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Rufinamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ruxolitinib (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab Govitecan: UGT1A1 Inducers may decrease serum concentrations of the active metabolite(s) of Sacituzumab Govitecan. Specifically, concentrations of SN-38 may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Samidorphan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: CarBAMazepine may decrease the serum concentration of Saquinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sertindole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: CarBAMazepine may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: CarBAMazepine may decrease the serum concentration of Siponimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus (Conventional).  Management: Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sofosbuvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stiripentol: CarBAMazepine may decrease the serum concentration of Stiripentol. Stiripentol may increase the serum concentration of CarBAMazepine.  Management: Avoid the use of stiripentol and carbamazepine when possible. If combined, monitor for both reduced stiripentol efficacy and increased carbamazepine concentrations and toxicities. Dose adjustments of both drugs may be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUFentanil.  Management: If a strong CYP3A4 inducer is initiated in a patient on sufentanil, consider a sufentanil dose increase and monitor for decreased sufentanil effects and opioid withdrawal symptoms.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulthiame: CarBAMazepine may decrease the serum concentration of Sulthiame. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If combined, increase sunitinib dose to a max of 87.5 mg daily when treating GIST or RCC. Increase sunitinib dose to a max of 62.5 mg daily when treating PNET. Monitor patients for both reduced efficacy and increased toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Tacrolimus (Systemic).  Management: Monitor for decreased tacrolimus concentrations and effects when combined with strong CYP3A4 inducers. Tacrolimus dose increases will likely be needed during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction or benign prostatic hypertrophy: monitor for decreased effectiveness - no standard dose adjustment is recommended. Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tasimelteon. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Taurursodiol. Specifically, the concentrations of phenylbutyrate may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Temsirolimus.  Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inducers. If coadministration is unavoidable, increase temsirolimus dose to 50 mg per week. Resume previous temsirolimus dose after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Alafenamide: CarBAMazepine may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol.  Management: Avoid use of the tetrahydrocannabinol/cannabidiol oromucosal spray and strong CYP3A4 inducers when possible. If combined use is necessary, careful titration is recommended, notably within the two weeks following discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CarBAMazepine may decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of CarBAMazepine.  Management: Seek alternatives to this combination when possible.  If these agents are used together, monitor closely for decreased serum concentrations/therapeutic effects of both medications.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Strong) may decrease the serum concentration of Thiotepa.  Management: Thiotepa prescribing information recommends avoiding concomitant use of thiotepa and strong CYP3A4 inducers. If concomitant use is unavoidable, monitor for adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: CarBAMazepine may decrease the serum concentration of Thiothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: CarBAMazepine may decrease the serum concentration of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiaGABine: CYP3A4 Inducers (Strong) may decrease the serum concentration of TiaGABine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tipranavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tivozanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Topiramate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: May enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CarBAMazepine may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of CarBAMazepine.  Management: Consider increasing the trazodone dose during coadministration with strong CYP3A4 inducers, such as carbamazepine. In addition, monitor for increased carbamazepine concentrations and effects during coadministration with trazodone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Treosulfan: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Triamcinolone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Triazolam.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced triazolam efficacy. Substantial triazolam dose increases will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: CarBAMazepine may decrease the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tropisetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tropisetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tucatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ubrogepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase serum concentrations of the active metabolite(s) of CarBAMazepine. Parent carbamazepine concentrations may be increased, decreased, or unchanged. CarBAMazepine may decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vecuronium: CarBAMazepine may decrease the serum concentration of Vecuronium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP2B6 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.  Management: Avoid coadministration of vemurafenib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase the vemurafenib dose by 240 mg as tolerated. Resume prior vemurafenib dose 2 weeks after discontinuation of strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Strong) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.  Management: Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg/day), based on response, in patients receiving strong CYP3A4 inducers for &gt; 14 days. Reduce to the original vilazodone dose over 1 to 2 weeks after inducer discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinorelbine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinorelbine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): CarBAMazepine may decrease the serum concentration of Vitamin K Antagonists.  Management: Monitor for decreased INR and effects of vitamin K antagonists if carbamazepine is initiated/dose increased, or increased INR and effects if carbamazepine is discontinued/dose decreased. Vitamin K antagonist dose adjustments will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: CarBAMazepine may decrease the serum concentration of Voriconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vortioxetine.  Management: Consider increasing the vortioxetine dose to no more than 3 times the original dose when used with a strong drug metabolism inducer for more than 14 days. The vortioxetine dose should be returned to normal within 14 days of stopping the strong inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and strong CYP3A4 inducers. If  unavoidable, increase the voxelotor dose to 2,500 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zaleplon.  Management: Consider the use of an alternative hypnotic that is not metabolized by CYP3A4 in patients receiving strong CYP3A4 inducers. If zaleplon is combined with a strong CYP3A4 inducer, monitor for decreased effectiveness of zaleplon.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zanubrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zavegepant: OATP1B1/1B3 (SLCO1B1/1B3) Inducers may decrease the serum concentration of Zavegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ziprasidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zonisamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zonisamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CarBAMazepine may enhance the CNS depressant effect of Zopiclone. CarBAMazepine may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F145583"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Carbamazepine serum levels may be increased if taken with food and/or grapefruit juice. Management: Monitor for increased toxic effects with concurrent ingestion of grapefruit juice. Maintain adequate hydration, unless instructed to restrict fluid intake.</p></div>
<div class="block dic drugH1Div" id="F49897364"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Folate and vitamin B: Carbamazepine use has been associated with low serum concentrations of folate, vitamin B<sub>2</sub> (riboflavin), B<sub>6</sub> (pyridoxine) and B<sub>12</sub> (cyanocobalamin), which may contribute to hyperhomocysteinemia. Hyperhomocysteinemia may contribute to cardiovascular disease, venous thromboembolic disease, dementia, neuropsychiatric symptoms, and poor seizure control. Some health care providers recommend administering folic acid, riboflavin, pyridoxine, and cyanocobalamin supplements in patients taking carbamazepine (Apeland 2003; Apeland 2008; Belcastro 2012; Bochyńska 2012).</p></div>
<div class="block rep_considerations drugH1Div" id="F53095497"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Carbamazepine may decrease plasma concentrations of hormonal contraceptives (consult drug interactions database); alternate or back-up methods of contraception should be considered.</p>
<p style="text-indent:0em;margin-top:2em;">Carbamazepine is associated with adverse pregnancy outcomes; when alternative therapies are not appropriate, folic acid supplementation is recommended for patients who could become pregnant.</p></div>
<div class="block pri drugH1Div" id="F145571"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Carbamazepine and its active metabolite cross the placenta; concentrations are variable but correlate with maternal serum concentrations (Kacirova 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Carbamazepine may be associated with teratogenic effects, including spina bifida, craniofacial defects, and cardiovascular malformations. Data from the International Registry of Antiepileptic Drugs and Pregnancy (EURAP) and the UK and Ireland Epilepsy Pregnancy Registers (UKEPR) note the risk of congenital malformations increases with higher doses (Campbell 2014; Tomson 2011). The risk of teratogenic effects is higher with antiseizure polytherapy than monotherapy. Developmental delays have also been observed following in utero exposure to carbamazepine (per manufacturer). Folic acid supplementation is recommended if treatment is required during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of carbamazepine may be altered; however, available studies have slightly conflicting results (Deligiannidis 2014; Tomson 2013). Therapeutic drug monitoring of carbamazepine is recommended in pregnant patients (Harden 2009; Hiemke 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Carbamazepine is not recommended for the treatment of bipolar disorder in pregnancy (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to carbamazepine is ongoing. Patients exposed to carbamazepine during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>
<div class="block mopp drugH1Div" id="F53565852"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to initiation: <i>HLA-B*1502</i> and <i>HLA-A*3101</i> genotype screening in patients with ancestry in genetically at-risk populations</p>
<p style="text-indent:-2em;margin-left:2em;">Baseline and periodic assessment: CBC with platelet count and differential, reticulocytes, serum iron, liver function, renal function (including BUN), urinalysis, serum sodium, and ophthalmic exam (including slit-lamp, funduscopy, and tonometry)</p>
<p style="text-indent:-2em;margin-left:2em;">As appropriate: Lipid panel, serum carbamazepine levels, thyroid function tests; pregnancy test; observe patient for excessive sedation, especially when instituting or increasing therapy; signs of rash or allergic reaction; suicidality (eg, suicidal thoughts, depression, behavioral changes)</p></div>
<div class="block rerp drugH1Div" id="F53565733"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Timing of serum samples: Drug concentrations vary between initiation of therapy and chronic administration due to metabolic autoinduction; frequent monitoring and dose adjustments may be required during this time; autoinduction is usually complete after 3 to 5 weeks of dosing</p>
<p style="text-indent:-2em;margin-left:2em;">Seizures: Therapeutic concentrations (usual): 4 to 12 mcg/mL (SI: 17 to 51 micromoles/L)</p></div>
<div class="block pha drugH1Div" id="F145547"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">In addition to antiseizure effects, carbamazepine has anticholinergic, antineuralgic, antidiuretic, muscle relaxant, antimanic, antidepressive, and antiarrhythmic properties; may depress activity in the nucleus ventralis of the thalamus or decrease synaptic transmission or decrease summation of temporal stimulation leading to neural discharge by limiting influx of sodium ions across cell membrane or other unknown mechanisms; stimulates the release of ADH and potentiates its action in promoting reabsorption of water; chemically related to tricyclic antidepressants</p></div>
<div class="block phk drugH1Div" id="F145566"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Slowly from the GI tract</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Neonates: 1.52 ± 0.5 L/kg (Rey 1979); Children: 1.94 ± 0.8 L/kg (Rey 1979); Adults: 0.59 to 2 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Carbamazepine: 75% to 90%, bound to alpha<sub>1</sub>-acid glycoprotein and nonspecific binding sites on albumin; may be decreased in newborns; Epoxide metabolite: 50%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Induces liver enzymes to increase metabolism and shorten half-life over time; metabolized in the liver by cytochrome P450 3A4 to active epoxide metabolite; epoxide metabolite is metabolized by epoxide hydrolase to the trans-diol metabolite; ratio of serum epoxide to carbamazepine concentrations may be higher in patients receiving polytherapy (vs monotherapy) and in infants (vs older children); boys may have faster carbamazepine clearances and may, therefore, require higher mg/kg/day doses of carbamazepine compared to girls of similar age and weight</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 75% to 85%; relative bioavailability of ER tablet to suspension: 89%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: <b>Note:</b> Half-life is variable because of autoinduction which is usually complete 3 to 5 weeks after initiation of a fixed carbamazepine regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">Carbamazepine: Initial: 25 to 65 hours; Extended release: 35 to 40 hours; Multiple doses: Children and Adolescents: Mean range: 3.1 to 20.8 hours (Battino 1995); Adults: 12 to 17 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Epoxide metabolite: Initial: 34 ± 9 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Unpredictable:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Multiple doses: Suspension: 1.5 hour; tablet: 4 to 5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Carbatrol, Equetro: 12 to 26 hours (single dose), 4 to 8 hours (multiple doses); Tegretol-XR: 3 to 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine 72% (1% to 3% as unchanged drug); feces (28%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F145574"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Carbatol | Fitzecalm | Tegretol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Actinerval | Carbagramon | Carbalando | Carbamacepina | Carbamat | Carbamazepina | Cmp | Conformal | Elebe | Tegretol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Deleptin | Neurotop | Neurotop retard | Tegretol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Tegretol | Teril</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anleptic | Cabretol | Carbazin | Carmapine | Carmaz | Cazep | Epilep | Tegretol | Zeptol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine merck-generics | Tegretol</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Tegretol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepin | Finlepsin | Neurotop | Stazepin | Tegretol | Timonil</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Anoril | Carbamazepina | Carbazol | Carmazin | Convulsan | Furp carbamazepina | Karbac | Tegretard | Tegretol | Tegrex | Tegrezin | Uni carbamaz | Vate</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine rivopharm | Carsol | Tegretol | Timonil</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Neurotop | Tegretol | Wijtol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Carbactol | Carbamazepina | Carmian | Eposal | Tegretal</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">De li duo | Li zhen | Tegretol | Temporol slow</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepina | Carbamazepina mk | Carbazol | Carbepil | Cetiril | Eposal | Neugeron | Sigilex | Tegretol | Tegretol retard | Vulsivan | Zacef</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo carbamazepine | Biston | Finlepsin | Neurotop | Tegretol | Timonil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Carba | Carba abz | Carba retard | Carbabeta | Carbadura | Carbaflux | Carbagamma | Carbamazepin | Carbamazepin 1a pharma | Carbamazepin al | Carbamazepin Aristo | Carbamazepin Heumann | Carbamazepin hexal | Carbamazepin rph | Carbamazepin Sandoz | Carbamazepin-neuraxpharm | Carbamazepin-ratiopharm | Carbium | Elpenor | Espa-lepsin | Finlepsin | Fokalepsin | Sirtal | Tegretal | Tegretal retard | Tegretol | Timonil | Timonil 150 retard | Timonil 200 retard | Timonil 300 retard | Timonil 400 retard | Timonil 600 retard</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Avaplex | Carbamazepina | Carbazep | Carmaven | Lugretol | Mazepin | Neugeron | Tegretol | Tegron | Teril | Versitol Retard | Vulsivan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Actebral | Actinerval | Apo Carbamazepina | Carbactol | Carbam | Carbamazepina | Carbamazepina cr | Carbamazepina retard | Carbastar | Carbazina | Cetiril | Orquizepina | Tegretol | Zeptol | Zeptol cr</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Carbalex | Carbamazepin | Carbamazepina normon | Carbamazepine ns | Carbasan | Finlepsin | Tegretol | Timonil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alextol | Arbateg | Carbapex | Carbatol | Epimazepine | Mazemal | Neurotop | Tegral | Tegrapin | Tegretol | Tonoclone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepina | Carbamazepina normon | Tegretol</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Carbatol | Tegretol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine essential pharma | Carbapin | Hermolepsin | Macrepan | Neurotol | Tegretol | Temporol | Trimonil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine g gam | Carbamazepine teva | Tegretol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Arbil mr | Carbagen | Carbamazepin arrow | Carbamazepine aps | Carbamazepine berk | Carbamazepine cox | Carbamazepine dc | Carbamazepine kent | Carbamazepine medreich | Epimaz | Tegretol | Teril | Teril sandoz | Timonil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Tegretol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo carbamazepine | Convuline | Convulzine | Cp Carba | Degranol | Noderin | Taver | Tegretol | Teril</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Tegretol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Azepal | Carbamazepin-b | Carbamazepine essential pharma | Finlepsin | Neurotop | Stazepine | Tegretol | Temporol slow | Timonil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bamgetol | Lepigo | Lepsitol | Tegretol | Temporol | Teril</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Gericarb | Tegretol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Carbi | Tegretol | Teril | Timonil</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acetol | Antilep | Carbacontin | Carbatol | Carmaz | Carmeg | Carz | Carzep | Carzine | Cezetol | Cizetol | Epilent | Epilep | Epinil | Epix | Epnil | Fobigone | Ictozep | Indtol | Magrelite CR | Majerol | Manocarb | Mazetol | Megrelite | Mezapin | Mezaril | Mezocar LA | Mzep | Neurotol | Normapine | Salicarb | Seizurone | Swiztol | Tazetol | Tegretol | Tegrital | Versitol | Versitol rtd | Zen | Zepcar | Zeptol | Zigma | Zigma CR</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Karbazepin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepina | Carbamazepina eg | Carbamazepina provvisoria | Carbamazepina zentiva | Tegretol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Carbatol | Carbazine | Neurotop | Tegretol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine amel | Kodapan | Lexin | Tegretol | Telesmin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Azepine | Carbagen | Carbas | Carbatol | Carbazin cr | Carbazina | Carebama | Carmapine | Eptol | Mazapine | Neurotrol | Progretaz | Storilat | Taver | Tegretol | Tegretol cr | Zen retard</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Atretol | Cabarol | Cabarol cr | Canemin | Carbamin | Carbamin cr | Carbapine | Carmapine | Carmazepine | Carmazepine cr | Carmine | Carmine cr | Daehwa carbamazepine | Eleptin | Epileptol | Epileptol cr | Tegerol | Tegretol | Tegretol cr | Timonil</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Tegretol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo carbamazepine | Neurotop | Tegretol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo carbamazepine | Biston | Carbadak | Carbalex | Carbamazepin | Carbasan | Carbatol | Finlepsin | Neurotop | Stazepin | Tegretol | Tegretol cr | Temporol slow | Timonil | Zeptol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Carbium | Tegretal | Tegretol | Tegretol cr</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Biston | Carbadak | Carbalex | Carbamazepin | Finlepsin | Fokalepsin | Neurotop | Stazepin | Tegretol | Tegretol cr | Temporol slow | Timonil | Zeptol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine normon | Crizepine | Tegretol | Zeptol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Apobace | Bioneuril | Brucarcer | Bufipina | Carbalan | Carbamazepina | Carbamazepina gi | Carbamazepina gi m | Carbazep | Carbazina | Carpin | Cinazel | Clostedal | Dateril | Kezepin | Neugeron | Neurolep | Pebanic | Rancepine | Sepibest | Solprexol | Tegretol | Tegretol lc | Trepina | Ultrepyl | Volutol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo carbamazepine | Carbatol | Carzepin | Mazetol | Taver | Tegretol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Carbimi | Carzepin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine A | Carbamazepine Gf | Carbamazepine Katwijk | Carbamazepine Ratiopharm | Carbamazepine sandoz | Carbymal | Tegretol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine EssPharma | Karbamazepin | Tegretol | Trimonil</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Tegretol | Tegretol cr | Teril</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Actebral | Apo Carbamazepina | Basitrol | Carbagretol | Carbalip | Carbamal | Carbamazepina | Carbapin | Carbatrol | Carbazin | Convutol | Tegretol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine Pacific | Carbapsy | Carbastal | Carbazedin | Carbazure | Carbilepp | Carbitol 200 er | Epazin | Epihold | Epikor | Lestremor | Mezacar | Tegretol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Azapin | Carbamazap | Carbanil | Carbawel | Carbazin | Carpaz | Cazap | Convul | Epicar | Epilepsin | Epileptol | Epilex | Episeiz | Epitab XR | Leptic | Lexopine | Mazetol | Megrital | Mezapine | Seizunil | Tabtol | Tegral | Teril | Xepil | Zynaps</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Amizepin | Biston | Finlepsin | Neurotop | Tegretol | Timonil</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine er | Carbatrol | Epitol | Tegretol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepina | Carbamazepina ApS | Carbamazepina wynn | Tegretol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Actinerval | Agital | Auration | Carbalando | Carbamazepina bilac | Carbamazepina dallas | Carbamazepina dasanti | Carbamazepina heisecke | Carbamazepina la sante | Carbamazepina pasteur | Carbamazepina whelp | Mexaden | Neocarb | Tegretol | Tegretol 400 lc</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fitzecalm | Tegretol | Tegretol CR</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Biston | Carbamazepin eel | Carbamazepina arena | Carbamazepina lph | Carbamazepina slavia | Carbamazepina terapia | Carbavim | Finlepsin | Karbapin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Actinerval | Apo carbamazepine | Carbalepsin | Carbamazepin | Carbapin | Carzepin | Fimazepsin | Finlepsin | Finzepin | Mazepin | Tegretol | Tegretol cr | Zeptol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Carbatol | Fitzecalm | Tegretol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Carbamazepine essential pharma | Hermolepsin | Karbamazepin | Tegretal retard | Tegretol | Trimonil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo carbamazepine | Mazetol | Neurotop | Tegretol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Epial | Neurotop | Tegretol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Biston | Neurotop | Tegretol | Timonil</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Antafit | Carba d m | Carbamin | Carbapin | Carbatol | Carbazene | Carbazine | Carmapine | Carpine | Carzepine | Convalin | Mapezine | Norlep | Panitol | Pantol | Taver | Tegretol | Zeptol cr</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Carbatol | Taver | Tegretol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Karazepin | Karbalex | Karbasif | Karberol | Kazepin | Tegretol | Temporol | Teril</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Camapine | Carbama | Carmapine | Carpine | Neurotol | Noderin | Tegol | Tegretol | Temporol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Carbalex | Carbamazepin | Carbamazepin forte | Carbapin | Carbasan | Finlepsin | Finlepsol | Mezacar | Mezacar sr | Tegretol | Timonil | Umitol | Zeptol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Carbadac | Carbas | Carbatol | Carzepin | Storilat | Tegretol | Tegretol cr | Zepin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Auration | Cacerpina | Carbamazepina | Carbamazepina FU | Carbizen | Conformal | Dobucar | Tegretol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anleptic | Carbamazepina | Carpin | Convulex | Tanfedin | Tegretol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Cazerol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cpl alliance carbamazepine | Degranol | Gulf carbamazepine | Rolab-carbamazepine | Tegretol | Zeptol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ar mazepine | Degranol | Karbapin | Sandoz carbamezapine | Tegretol | Tegretol cr | Zen</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Apo carbamazepine | Epicarb | Tegretol | Tegretol cr | Torbarec</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>ACOG Committee on Practice Bulletins-Obstetrics, "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation," <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28256714">
<a name="28256714"></a>Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MSY, Phillips EJ. Recent advances in the understanding of severe cutaneous adverse reactions. <i>Br J Dermatol</i>. 2017;177(5):1234-1247. doi:10.1111/bjd.15423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/28256714/pubmed" id="28256714" target="_blank">28256714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25369238">
<a name="25369238"></a>Ahluwalia J, Abuabara K, Perman MJ, Yan AC. Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome. <i>Br J Dermatol</i>. 2015;172(4):1090-1095. doi:10.1111/bjd.13512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/25369238/pubmed" id="25369238" target="_blank">25369238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34178519">
<a name="34178519"></a>Ali A, Anugwom GO, Naqvi W, Saeeduddin MO, Singh R. A case of carbamazepine-induced acute pancreatitis: a rare etiology. <i>Cureus</i>. 2021;13(5):e15199. doi:10.7759/cureus.15199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/34178519/pubmed" id="34178519" target="_blank">34178519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24597466">
<a name="24597466"></a>Amstutz U, Shear NH, Rieder MJ, et al; CPNDS Clinical Recommendation Group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. <i>Epilepsia</i>. 2014;55(4):496-506. doi:10.1111/epi.12564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/24597466/pubmed" id="24597466" target="_blank">24597466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24122696">
<a name="24122696"></a>Anderson GD, Hakimian S. Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. <i>Clin Pharmacokinet</i>. 2014;53(1):29-49. doi: 10.1007/s40262-013-0107-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/24122696/pubmed" id="24122696" target="_blank">24122696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30926241">
<a name="30926241"></a>Andrade RJ; European Association for the Study of the Liver panel members. EASL clinical practice guidelines: drug-induced liver injury. <i>J Hepatol</i>. 2019;70(6):1222-1261. doi:10.1016/j.jhep.2019.02.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/30926241/pubmed" id="30926241" target="_blank">30926241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18644700">
<a name="18644700"></a>Apeland T, Frøyland ES, Kristensen O, Strandjord RE, Mansoor MA. Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins. <i>Epilepsy Res</i>. 2008;82(1):1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/18644700/pubmed" id="18644700" target="_blank">18644700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766014">
<a name="12766014"></a>Apeland T, Mansoor MA, Pentieva K, McNulty H, Strandjord RE. Fasting and post-methionine loading concentrations of homocysteine, vitamin B2, and vitamin B6 in patients on antiepileptic drugs. <i>Clin Chem</i>. 2003;49(6 Pt 1):1005-1008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/12766014/pubmed" id="12766014" target="_blank">12766014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818889">
<a name="20818889"></a>Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. <i>N Engl J Med</i>. 2010;363(6):542-551. doi:10.1056/NEJMoa0909801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/20818889/pubmed" id="20818889" target="_blank">20818889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35815232">
<a name="35815232"></a>Assaedi LM, Alshamrani HM, Abbas RA, Alghamdi FA. Carbamazepine-induced reversible vitiligo. <i>JAAD Case Rep</i>. 2022;26:3-5. doi:10.1016/j.jdcr.2022.05.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/35815232/pubmed" id="35815232" target="_blank">35815232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23429633">
<a name="23429633"></a>Atalay E, Tamçelik N, Capar O. High intraocular pressure after carbamazepine and gabapentin intake in a pseudoexfoliative patient. <i>J Glaucoma</i>. 2014;23(8):574-576. doi:10.1097/IJG.0b013e318287aca7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/23429633/pubmed" id="23429633" target="_blank">23429633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30951222">
<a name="30951222"></a>Atanasković-Marković M, Janković J, Tmušić V, et al. Hypersensitivity reactions to antiepileptic drugs in children. <i>Pediatr Allergy Immunol</i>. 2019;30(5):547-552. doi:10.1111/pai.13055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/30951222/pubmed" id="30951222" target="_blank">30951222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23269131">
<a name="23269131"></a>Barr J, Fraser G, Puntillo K, et al; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. <i>Crit Care Med.</i> 2013;41(1):263-306. doi: 10.1097/CCM.0b013e3182783b72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/23269131/pubmed" id="23269131" target="_blank">23269131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8582119">
<a name="8582119"></a>Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. <i>Clin Pharmacokinet</i>. 1995;29(5):341-369.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/8582119/pubmed" id="8582119" target="_blank">8582119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24099051">
<a name="24099051"></a>Beghi E, Giussani G, Grosso S, et al. Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy. <i>Epilepsia</i>. 2013;54(suppl 7):S2-S12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/24099051/pubmed" id="24099051" target="_blank">24099051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22824326">
<a name="22824326"></a>Belcastro V, Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. <i>Epilepsy Res</i>. 2012;102(1-2):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/22824326/pubmed" id="22824326" target="_blank">22824326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453718">
<a name="19453718"></a>Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. Suicide in people with epilepsy: how great is the risk? <i>Epilepsia</i>. 2009;50(8):1933-1942. doi:10.1111/j.1528-1167.2009.02106.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/19453718/pubmed" id="19453718" target="_blank">19453718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28190254">
<a name="28190254"></a>Bellivier F, Belzeaux R, Scott J, Courtet P, Golmard JL, Azorin JM. Anticonvulsants and suicide attempts in bipolar I disorders. <i>Acta Psychiatr Scand</i>. 2017;135(5):470-478. doi:10.1111/acps.12709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/28190254/pubmed" id="28190254" target="_blank">28190254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8444328">
<a name="8444328"></a>Berg I, Butler A, Ellis M, Foster J. Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. <i>Dev Med Child Neurol</i>. 1993;35(2):149-157. doi:10.1111/j.1469-8749.1993.tb11616.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/8444328/pubmed" id="8444328" target="_blank">8444328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30955419">
<a name="30955419"></a>Bermeo-Ovalle A. Making rash decisions in epilepsy: evaluating hypersensitivity reactions to anti-seizure medications. <i>Epilepsy Curr</i>. 2019;19(2):96-98. doi:10.1177/1535759719835672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/30955419/pubmed" id="30955419" target="_blank">30955419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9577998">
<a name="9577998"></a>Besag FM, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? <i>Epilepsia</i>. 1998;39(2):183-187. doi:10.1111/j.1528-1157.1998.tb01356.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/9577998/pubmed" id="9577998" target="_blank">9577998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18341684">
<a name="18341684"></a>Björnsson E. Hepatotoxicity associated with antiepileptic drugs. <i>Acta Neurol Scand</i>. 2008;118(5):281-290. doi:10.1111/j.1600-0404.2008.01009.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/18341684/pubmed" id="18341684" target="_blank">18341684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25933949">
<a name="25933949"></a>Błaszczyk B, Lasoń W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: An update. <i>Pharmacol Rep</i>. 2015;67(3):426-434. doi:10.1016/j.pharep.2014.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/25933949/pubmed" id="25933949" target="_blank">25933949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23744424">
<a name="23744424"></a>Błaszczyk B, Szpringer M, Czuczwar SJ, Lasoń W. Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions. <i>Pharmacol Rep</i>. 2013;65(2):399-409. doi:10.1016/s1734-1140(13)71015-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/23744424/pubmed" id="23744424" target="_blank">23744424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bobo.1">
<a name="Bobo.1"></a>Bobo WV, Shelton RC. Bipolar major depression in adults: Efficacy and adverse effects of antidepressants. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22360846">
<a name="22360846"></a>Bochyńska A, Lipczyńska-Łojkowska W, Gugała-Iwaniuk M, et al. The effect of vitamin B supplementation on homocysteine metabolism and clinical state of patients with chronic epilepsy treated with carbamazepine and valproic acid. <i>Seizure</i>. 2012;21(4):276-281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/22360846/pubmed" id="22360846" target="_blank">22360846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24444855">
<a name="24444855"></a>Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. <i>J Neurol Neurosurg Psychiatry</i>. 2014;85(9):1029-1034.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/24444855/pubmed" id="24444855" target="_blank">24444855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carbatrol.1">
<a name="Carbatrol.1"></a>Carbatrol (carbamazepine) [prescribing information]. Lexington, MA: Shire US; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carbatrol.2">
<a name="Carbatrol.2"></a>Carbatrol (carbamazepine) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carbamazepine.1">
<a name="Carbamazepine.1"></a>Carbamazepine [prescribing information] tablets and chewable tablets. Parsippany, NJ: Teva Pharmaceuticals; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24387898">
<a name="24387898"></a>Chen MJ, Zhang WJ, Guo ZL, Zhang WH, Chai Y, Li YW. Withdrawal reaction of carbamazepine after neurovascular decompression for trigeminal neuralgia: a preliminary study. <i>J Neurol Sci.</i> 2014;338(1-2):43-45. doi: 10.1016/j.jns.2013.12.013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/24387898/pubmed" id="24387898" target="_blank">24387898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33188522">
<a name="33188522"></a>Chung SJ, Ahn KM, Oh JH, Shim JS, Park HW. Incidence rates of severe cutaneous adverse reactions due to antiseizure medication: a nationwide study using health claims data in Korea. <i>Epilepsia</i>. 2021;62(1):250-257. doi:10.1111/epi.16751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/33188522/pubmed" id="33188522" target="_blank">33188522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7667170">
<a name="7667170"></a>Cooney GF, Mochon M, Kaiser B, et al, “Effects of Carbamazepine on Cyclosporine Metabolism in Pediatric Renal Transplant Recipients,” <i>Pharmacotherapy</i>, 1995, 15(3):353-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7667170/pubmed" id="7667170" target="_blank">7667170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1175419">
<a name="1175419"></a>Cullinan SA, Bower GC. Acute pulmonary hypersensitivity to carbamazepine. <i>Chest</i>. 1975;68(4):580-581. doi:10.1378/chest.68.4.580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/1175419/pubmed" id="1175419" target="_blank">1175419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8729227">
<a name="8729227"></a>Dang CT, Riley DK. Aseptic meningitis secondary to carbamazepine therapy. <i>Clin Infect Dis</i>. 1996;22(4):729-730. doi:10.1093/clinids/22.4.729<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/8729227/pubmed" id="8729227" target="_blank">8729227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12476936">
<a name="12476936"></a>Dasgupta A. Clinical utility of free drug monitoring.<i> Clin Chem Lab Med</i>. 2002;40(10):986-993. doi:10.1515/CCLM.2002.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/12476936/pubmed" id="12476936" target="_blank">12476936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7624911">
<a name="7624911"></a>Dasgupta A, Thompson WC. Carbamazepine-salicylate interaction in normal and uremic sera: reduced interaction in uremic sera. <i>Ther Drug Monit</i>. 1995;17(2):199-202. doi:10.1097/00007691-199504000-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7624911/pubmed" id="7624911" target="_blank">7624911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24525634">
<a name="24525634"></a>Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. <i>J Clin Psychopharmacol</i>. 2014;34(2):244-255.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/24525634/pubmed" id="24525634" target="_blank">24525634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24879980">
<a name="24879980"></a>Devarbhavi H, Andrade RJ. Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. <i>Semin Liver Dis</i>. 2014;34(2):145-161. doi:10.1055/s-0034-1375956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/24879980/pubmed" id="24879980" target="_blank">24879980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Epitol.1">
<a name="Epitol.1"></a>Epitol (carbamazepine) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Equetro.1">
<a name="Equetro.1"></a>Equetro (carbamazepine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34933835">
<a name="34933835"></a>Fohlen M, Taussig D, Bulteau C, Audren F. Reversible downbeat nystagmus induced by carbamazepine in a three-year-old child. <i>Epileptic Disord</i>. 2022;24(2):435-437. doi:10.1684/epd.2021.1400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/34933835/pubmed" id="34933835" target="_blank">34933835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29027197">
<a name="29027197"></a>Frey N, Bodmer M, Bircher A, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. <i>Epilepsia</i>. 2017;58(12):2178-2185. doi:10.1111/epi.13925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/29027197/pubmed" id="29027197" target="_blank">29027197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29898616">
<a name="29898616"></a>Fricke-Galindo I, LLerena A, Jung-Cook H, López-López M. Carbamazepine adverse drug reactions. <i>Expert Rev Clin Pharmacol</i>. 2018;11(7):705-718. doi:10.1080/17512433.2018.1486707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/29898616/pubmed" id="29898616" target="_blank">29898616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6390794">
<a name="6390794"></a>Froescher W, Eichelbaum M, Niesen M, et al, "Carbamazepine Levels in Breast Milk," <i>Ther Drug Monit</i>, 1984, 6(3):266-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/6390794/pubmed" id="6390794" target="_blank">6390794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7591369">
<a name="7591369"></a>Furst SM and Uetrecht JP, “The Effect of Carbamazepine and Its Reactive Metabolite 9-Acridine Carboxaldehyde, on Immune Cell Function <i>in vitro</i>,” <i>Int J Immunopharmacol</i>, 1995, 17(5):445-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7591369/pubmed" id="7591369" target="_blank">7591369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29200572">
<a name="29200572"></a>Ganesh S, Shukla L, Kandasamy A, Benegal V. A case of carbamazepine-induced severe cholestatic hepatitis: case report and review of literature. <i>Indian J Psychol Med</i>. 2017;39(5):688-690. doi:10.4103/IJPSYM.IJPSYM_19_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/29200572/pubmed" id="29200572" target="_blank">29200572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1803802">
<a name="1803802"></a>Gilman JT, “Carbamazepine Dosing for Pediatric Seizure Disorders: The Highs and Lows,” <i>DICP</i>, 1991, 25(10):1109-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/1803802/pubmed" id="1803802" target="_blank">1803802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26979387">
<a name="26979387"></a>Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. <i>J Psychopharmacol.</i> 2016;30(6):495-553. doi: 10.1177/0269881116636545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/26979387/pubmed" id="26979387" target="_blank">26979387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3334021">
<a name="3334021"></a>Graves NM, Kriel RL. Rectal administration of antiepileptic drugs in children. <i>Pediatr Neurol</i>. 1987;3(6):321-326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/3334021/pubmed" id="3334021" target="_blank">3334021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11507366">
<a name="11507366"></a>Grieco A, Alfei B, Di Rocco P, et al. Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria. <i>Eur J Gastroenterol Hepatol</i>. 2001;13(8):973-975. doi:10.1097/00042737-200108000-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/11507366/pubmed" id="11507366" target="_blank">11507366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19347775">
<a name="19347775"></a>Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania [published correction appears in <i>World J Biol Psychiatry.</i> 2009;10(3):255]. <i>World J Biol Psychiatry.</i> 2009;10(2):85-116. doi: 10.1080/15622970902823202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/19347775/pubmed" id="19347775" target="_blank">19347775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29501520">
<a name="29501520"></a>Guvenir H, Dibek Misirlioglu E, Civelek E, et al. The frequency and clinical features of hypersensitivity reactions to antiepileptic drugs in children: a prospective study. <i>J Allergy Clin Immunol Pract</i>. 2018;6(6):2043-2050. doi:10.1016/j.jaip.2018.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/29501520/pubmed" id="29501520" target="_blank">29501520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2334214">
<a name="2334214"></a>Hadzić N, Portmann B, Davies ET, Mowat AP, Mieli-Vergani G. Acute liver failure induced by carbamazepine. <i>Arch Dis Child</i>. 1990;65(3):315-317. doi:10.1136/adc.65.3.315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/2334214/pubmed" id="2334214" target="_blank">2334214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28974841">
<a name="28974841"></a>Hadzagic-Catibusic F, Hasanbegovic E, Melunovic M, Zubcevic S, Uzicanin S. Effects of carbamazepine and valproate on serum aspartate aminotransferase, alanine aminotransferase and gamma - glutamyltransferase in children. <i>Med Arch</i>. 2017;71(4):239-242. doi:10.5455/medarh.2017.71.239-242<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/28974841/pubmed" id="28974841" target="_blank">28974841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9016432">
<a name="9016432"></a>Hans P, Brichant JF, Pieron F, et al, “Elevated Plasma Alpha 1-Acid Glycoprotein Levels: Lack of Connection to Resistance to Vecuronium Blockade Induced by Anticonvulsant Therapy,” <i>J Neurosurg Anesthesiol</i>, 1997, 9(1):3-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/9016432/pubmed" id="9016432" target="_blank">9016432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398682">
<a name="19398682"></a>Harden CL, Hopp J, Ting TY, et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology.</i> 2009;73(2):126-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/19398682/pubmed" id="19398682" target="_blank">19398682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496806">
<a name="19496806"></a>Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? <i>Epilepsia</i>. 2009;50(5):978-986. doi:10.1111/j.1528-1167.2009.02012.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/19496806/pubmed" id="19496806" target="_blank">19496806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirschfeld.1">
<a name="Hirschfeld.1"></a>Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder, 2nd ed. Washington, DC: American Psychiatric Association; April 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18078476">
<a name="18078476"></a>Hmouda H, Ben Salem C, Grira M, Slim R, Bouraoui K. Carbamazepine-induced urinary retention. <i>Br J Clin Pharmacol</i>. 2007;64(6):833-834. doi:10.1111/j.1365-2125.2007.03002.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/18078476/pubmed" id="18078476" target="_blank">18078476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ho.1">
<a name="Ho.1"></a>Ho CC, Khan SA, Whealy MA. Trigeminal neuralgia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9343147">
<a name="9343147"></a>Ikeda A, Shibasaki H, Shiozaki A, Kimura J. Alopecia with carbamazepine in two patients with focal seizures. <i>J Neurol Neurosurg Psychiatry</i>. 1997;63(4):549-550. doi:10.1136/jnnp.63.4.549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/9343147/pubmed" id="9343147" target="_blank">9343147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8635181">
<a name="8635181"></a>Iwahashi IS, Miyatake R, Suwaki H, et al, “The Drug-Drug Interaction Effects of Haloperidol on Plasma Carbamazepine Levels,” <i>Clin Neuropharmacol</i>, 1995, 18:233-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/8635181/pubmed" id="8635181" target="_blank">8635181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8107947">
<a name="8107947"></a>Jubert P, Almirall J, Casanovas A, Garcia M. Carbamazepine-induced acute renal failure. <i>Nephron</i>. 1994;66(1):121. doi:10.1159/000187784<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/8107947/pubmed" id="8107947" target="_blank">8107947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kacirova.1">
<a name="Kacirova.1"></a>Kacirova I, Grundmann M, Brozmanova H. Therapeutic monitoring of carbamazepine concentrations in breastfeeding mothers, maternal milk and nursed infants. <i>Ther Drug Monit</i>. 2011;33:503.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26991491">
<a name="26991491"></a>Kacirova I, Grundmann M, Brozmanova H. Concentrations of carbamazepine and carbamazepine-10,11-epoxide in maternal and umbilical cord blood at birth: Influence of co-administration of valproic acid or enzyme-inducing antiepileptic drugs. <i>Epilepsy Res</i>. 2016;122:84-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/26991491/pubmed" id="26991491" target="_blank">26991491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31198759">
<a name="31198759"></a>Kaeley N, Kabi A, Bhatia R, Mohanty A. Carbamazepine-induced hyponatremia - a wakeup call. <i>J Family Med Prim Care</i>. 2019;8(5):1786-1788. doi:10.4103/jfmpc.jfmpc_185_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/31198759/pubmed" id="31198759" target="_blank">31198759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-465285">
<a name="465285"></a>Kaneko S, Sato T, Suzuki K. The levels of anticonvulsants in breast milk. <i>Br J Clin Pharmacol</i>. 1979;7(6):624-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/465285/pubmed" id="465285" target="_blank">465285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1295628">
<a name="1295628"></a>Kanno T, Miyata M, Kazuta Y, Sato Y, Nishimaki T, Kasukawa R. Carbamazepine-induced systemic lupus erythematosus-like disease. <i>Intern Med</i>. 1992;31(11):1303-1305. doi:10.2169/internalmedicine.31.1303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/1295628/pubmed" id="1295628" target="_blank">1295628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1728915">
<a name="1728915"></a>Kasarskis EJ, Kuo CS, Berger R, Nelson KR. Carbamazepine-induced cardiac dysfunction. Characterization of two distinct clinical syndromes. <i>Arch Intern Med</i>. 1992;152(1):186-191. doi:10.1001/archinte.152.1.186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/1728915/pubmed" id="1728915" target="_blank">1728915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7655141">
<a name="7655141"></a>Keating A and Blahunka P, “Carbamazepine-Induced Stevens-Johnson Syndrome in a Child,” <i>Ann Pharmacother</i>, 1995, 29(5):538-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7655141/pubmed" id="7655141" target="_blank">7655141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2017974">
<a name="2017974"></a>Kennebäck G, Bergfeldt L, Vallin H, Tomson T, Edhag O. Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. <i>Am Heart J</i>. 1991;121(5):1421-1429. doi:10.1016/0002-8703(91)90148-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/2017974/pubmed" id="2017974" target="_blank">2017974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18698874">
<a name="18698874"></a>Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. <i>CNS Drugs</i>. 2008;22(9):739-760. doi:10.2165/00023210-200822090-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/18698874/pubmed" id="18698874" target="_blank">18698874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15163253">
<a name="15163253"></a>Ketter TA, Kalali AH, and Weisler RH, “A 6-Month, Multicenter, Open-Label Evaluation of Beaded, Extended-Release Carbamazepine Capsule Monotherapy in Bipolar Disorder Patients With Manic or Mixed Episodes: SPD417 Study Group,” <i>J Clin Psychiatry</i>, 2004, 65(5):668-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/15163253/pubmed" id="15163253" target="_blank">15163253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26969368">
<a name="26969368"></a>Khoo AB, Ali FR, Yiu ZZ, Ferguson JE. Carbamazepine induced Stevens-Johnson syndrome. <i>BMJ Case Rep</i>. 2016;2016:bcr2016214926. doi:10.1136/bcr-2016-214926<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/26969368/pubmed" id="26969368" target="_blank">26969368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11093063">
<a name="11093063"></a>Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. <i>Neuropsychobiology</i>. 2000;42(suppl 1):2-10. doi: 10.1159/000054844.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/11093063/pubmed" id="11093063" target="_blank">11093063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22794330">
<a name="22794330"></a>Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. <i>Expert Opin Drug Saf</i>. 2012;11(5):767-778. doi:10.1517/14740338.2012.705828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/22794330/pubmed" id="22794330" target="_blank">22794330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7824094">
<a name="7824094"></a>Korinthenberg R, Haug C, and Hannak D, “The Metabolization of Carbamazepine to CBZ-10,11 Epoxide in Children From the Newborn Age to Adolescence,” <i>Neuropediatrics</i>, 1994, 25(4):214-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7824094/pubmed" id="7824094" target="_blank">7824094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25336888">
<a name="25336888"></a>Koutsampasopoulos K, Zotos A, Papamichalis M, Papaioannou K. Carbamazepine induced atrial tachycardia with complete AV block. <i>Hippokratia</i>. 2014;18(2):185-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/25336888/pubmed" id="25336888" target="_blank">25336888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16189283">
<a name="16189283"></a>Kuz GM, Manssourian A. Carbamazepine-induced hyponatremia: assessment of risk factors. <i>Ann Pharmacother</i>. 2005;39(11):1943-1946. doi:10.1345/aph.1G209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/16189283/pubmed" id="16189283" target="_blank">16189283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leach.1">
<a name="Leach.1"></a>Leach JP. Antiepileptic drug therapy. In: <i>Encyclopedia of the Neurological Sciences</i>. Vol 1. Elsevier; 2014:224-232.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23695185">
<a name="23695185"></a>Leckband SG, Kelsoe JR, Dunnenberger HM, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.<i> Clin Pharmacol Ther.</i> 2013;94(3):324-328. doi:10.1038/clpt.2013.103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/23695185/pubmed" id="23695185" target="_blank">23695185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7449356">
<a name="7449356"></a>Lee CS, Wang LH, Marbury TC, Bruni J, Perchalski RJ. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. <i>Clin Toxicol</i>. 1980;17(3):429-438. doi: 10.3109/15563658008989993.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7449356/pubmed" id="7449356" target="_blank">7449356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8610843">
<a name="8610843"></a>Leo RJ, Cannuli AR. Porphyria cutanea tarda associated with carbamazepine treatment. <i>Am J Psychiatry</i>. 1996;153(3):443-444. doi:10.1176/ajp.153.3.443b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/8610843/pubmed" id="8610843" target="_blank">8610843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3546274">
<a name="3546274"></a>Lerer B, Moore N, Meyendorff E, et al, “Carbamazepine Versus Lithium in Mania: A Double-Blind Study,” <i>J Clin Psychiatry</i>, 1987, 48(3):89-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/3546274/pubmed" id="3546274" target="_blank">3546274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7247130">
<a name="7247130"></a>Levy M, Goodman MW, Van Dyne BJ, Sumner HW. Granulomatous hepatitis secondary to carbamazepine. <i>Ann Intern Med</i>. 1981;95(1):64-65. doi:10.7326/0003-4819-95-1-64<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7247130/pubmed" id="7247130" target="_blank">7247130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22211830">
<a name="22211830"></a>Lin YT, Chang YC, Hui RC, et al. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. <i>J Eur Acad Dermatol Venereol</i>. 2013;27(3):356-364. doi:10.1111/j.1468-3083.2011.04418.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/22211830/pubmed" id="22211830" target="_blank">22211830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7846744">
<a name="7846744"></a>Liu H and Delgado MR, “Influence of Sex, Age, Weight, and Carbamazepine Dose on Serum Concentrations, Concentration Ratios, and Level/Dose Ratios of Carbamazepine and Its Metabolites,” <i>Ther Drug Monit</i>, 1994, 16(5):469-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7846744/pubmed" id="7846744" target="_blank">7846744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20213839">
<a name="20213839"></a>Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). <i>J Pharm Sci</i>. 2010;99(8):3291-3301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/20213839/pubmed" id="20213839" target="_blank">20213839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27587068">
<a name="27587068"></a>Mahmoud SH. Antiepileptic drug removal by continuous renal replacement therapy: a review of the literature. <i>Clin Drug Investig</i>. 2017;37(1):7-23. doi: 10.1007/s40261-016-0457-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/27587068/pubmed" id="27587068" target="_blank">27587068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10799630">
<a name="10799630"></a>Matos ME, Burns MM, and Shannon MW, “False-Positive Tricyclic Antidepressant Drug Screen Results Leading to the Diagnosis of Carbamazepine Intoxication,” <i>Pediatrics</i>, 2000, 105(5):e66<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/10799630/pubmed" id="10799630" target="_blank">10799630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21428769">
<a name="21428769"></a>McCormack M, Alfirevic A, Bourgeois S, et al, "HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans,"<i> N Engl J Med</i>, 2011, 364(12):1134-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/21428769/pubmed" id="21428769" target="_blank">21428769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1673736">
<a name="1673736"></a>Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. <i>Lancet</i>. 1991;337(8751):1175-1180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/1673736/pubmed" id="1673736" target="_blank">1673736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mehrizi.1">
<a name="Mehrizi.1"></a>Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. <i>Medications and Myasthenia Gravis (a Reference for Health Care Professionals)</i>. Indiana University School of Medicine's Department of Neurology; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24554914">
<a name="24554914"></a>Mehta M, Shah J, Khakhkhar T, Shah R, Hemavathi KG. Anticonvulsant hypersensitivity syndrome associated with carbamazepine administration: case series. <i>J Pharmacol Pharmacother</i>. 2014;5(1):59-62. doi:10.4103/0976-500X.124428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/24554914/pubmed" id="24554914" target="_blank">24554914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2371100">
<a name="2371100"></a>Miles MV, Lawless ST, Tennison MB, et al, “Rapid Loading of Critically Ill Patients With Carbamazepine Suspension,” <i>Pediatrics</i>, 1990, 86(2):263-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/2371100/pubmed" id="2371100" target="_blank">2371100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27086495">
<a name="27086495"></a>Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. <i>Am J Med</i>. 2016;129(11):1221-1225. doi:10.1016/j.amjmed.2016.03.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/27086495/pubmed" id="27086495" target="_blank">27086495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33200428">
<a name="33200428"></a>Mintzer S, Dimova S, Zhang Y, et al. Effects of lacosamide and carbamazepine on lipids in a randomized trial. <i>Epilepsia</i>. 2020;61(12):2696-2704. doi:10.1111/epi.16745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/33200428/pubmed" id="33200428" target="_blank">33200428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2362393">
<a name="2362393"></a>Mizukami K, Naito Y, Yoshida M, Nakanishi T, Koizumi J. Mental disorders induced by carbamazepine. <i>Jpn J Psychiatry Neurol</i>. 1990;44(1):59-63. doi:10.1111/j.1440-1819.1990.tb00441.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/2362393/pubmed" id="2362393" target="_blank">2362393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30259204">
<a name="30259204"></a>Mora Rodríguez KA, Benbadis SR. Managing antiepileptic medication in dialysis patients. <i>Curr Treat Options Neurol</i>. 2018;20(11):45. doi: 10.1007/s11940-018-0530-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/30259204/pubmed" id="30259204" target="_blank">30259204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22994856">
<a name="22994856"></a>Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. <i>Epilepsia</i>. 2013;54(1):199-203. doi:10.1111/j.1528-1167.2012.03688.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/22994856/pubmed" id="22994856" target="_blank">22994856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 3, 2014. Accessed October 15, 2021. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1948228">
<a name="1948228"></a>O'Griofa FM, Voris JC. Neuroleptic malignant syndrome associated with carbamazepine. <i>South Med J</i>. 1991;84(11):1378-1380. doi:10.1097/00007611-199111000-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/1948228/pubmed" id="1948228" target="_blank">1948228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-119267">
<a name="119267"></a>Okuma T, Inanaga K, Otsuki S, et al, “Comparison of the Antimanic Efficacy of Carbamazepine and Chlorpromazine: A Double-Blind Controlled Study,” <i>Psychopharmacology</i>, 1979, 66(3):211-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/119267/pubmed" id="119267" target="_blank">119267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8162652">
<a name="8162652"></a>Ory JP, Bourscheld D, Lebrun C, et al, “Drug-Induced Pseudolymphoma in a Lupus Patient: One Case Due to Carbamazepine,” <i>Clin Exp Rheumatol</i>, 1995, 12(Suppl 11):93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/8162652/pubmed" id="8162652" target="_blank">8162652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31899808">
<a name="31899808"></a>Oussalah A, Yip V, Mayorga C, et al. Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: a PRISMA-compliant systematic review-An EAACI position paper. <i>Allergy</i>. 2020;75(5):1069-1098. doi:10.1111/all.14174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/31899808/pubmed" id="31899808" target="_blank">31899808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69. doi: 10.1161/CIR.0000000000000426.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15976235">
<a name="15976235"></a>Pandey CK, Raza M, Tripathi M, Navkar DV, Kumar A, Singh UK. The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. <i>Anesth Analg</i>. 2005;101(1):220-225. doi: 10.1213/01.ANE.0000152186.89020.36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/15976235/pubmed" id="15976235" target="_blank">15976235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31332981">
<a name="31332981"></a>Park CS, Kang DY, Kang MG, et al. Severe cutaneous adverse reactions to antiepileptic drugs: a nationwide registry-based study in Korea. <i>Allergy Asthma Immunol Res</i>. 2019;11(5):709-722. doi:10.4168/aair.2019.11.5.709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/31332981/pubmed" id="31332981" target="_blank">31332981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29957667">
<a name="29957667"></a>Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. <i>Ther Drug Monit</i>. 2018;40(5):526-548. doi:10.1097/FTD.0000000000000546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/29957667/pubmed" id="29957667" target="_blank">29957667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7849350">
<a name="7849350"></a>Patterson BD, “Possible Interaction Between Metronidazole and Carbamazepine,” <i>Ann Pharmacother</i>, 1994, 28(11):1303-1304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7849350/pubmed" id="7849350" target="_blank">7849350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20388896">
<a name="20388896"></a>Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death [published correction appears in <i>JAMA</i>. 2010;303(22):2252]. <i>JAMA</i>. 2010;303(14):1401-1409. doi:10.1001/jama.2010.410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/20388896/pubmed" id="20388896" target="_blank">20388896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12044369">
<a name="12044369"></a>Pedley TA, Hauser WA. Sudden death in epilepsy: a wake-up call for management. <i>Lancet</i>. 2002;359(9320):1790-1791. doi:10.1016/S0140-6736(02)08726-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/12044369/pubmed" id="12044369" target="_blank">12044369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26523730">
<a name="26523730"></a>Peselow ED, Clevenger S, IsHak WW. Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study. <i>Int Clin Psychopharmacol.</i> 2016;31(4):218-223. doi: 10.1097/YIC.0000000000000097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/26523730/pubmed" id="26523730" target="_blank">26523730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29392710">
<a name="29392710"></a>Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. <i>Clin Pharmacol Ther</i>. 2018;103(4):574-581. doi:10.1002/cpt.1004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/29392710/pubmed" id="29392710" target="_blank">29392710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3093468">
<a name="3093468"></a>Placidi GF, Lenzi A, Lazzerini F, et al, “The Comparative Efficacy and Safety of Carbamazepine Versus Lithium: A Randomized, Double-blind 3-year Trial in 83 Patients,” <i>J Clin Psychiatry</i>, 1986, 47(10):490-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/3093468/pubmed" id="3093468" target="_blank">3093468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.1">
<a name="Post.1"></a>Post RM. Bipolar disorder in adults: choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18340692">
<a name="18340692"></a>Rabins PV, Blacker D, Rovner BW, et al, “American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,” <i>Am J Psychiatry</i>, 2007, 164(12 Suppl):5-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/18340692/pubmed" id="18340692" target="_blank">18340692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12352223">
<a name="12352223"></a>Ramos AM, Gayotto LC, Clemente CM, Mello ES, Luz KG, Freitas ML. Reversible vanishing bile duct syndrome induced by carbamazepine. <i>Eur J Gastroenterol Hepatol</i>. 2002;14(9):1019-1022. doi:10.1097/00042737-200209000-00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/12352223/pubmed" id="12352223" target="_blank">12352223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9407192">
<a name="9407192"></a>Reiffers-Mettelock J, Hentges F, Humbel RL. Syndrome resembling systemic lupus erythematosus induced by carbamazepine. <i>Dermatology</i>. 1997;195(3):306. doi:10.1159/000245973<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/9407192/pubmed" id="9407192" target="_blank">9407192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29467570">
<a name="29467570"></a>Reimers A, Berg JA, Burns ML, et al. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. <i>Drug Des Devel Ther</i>. 2018;12:271-280. doi:10.2147/DDDT.S154388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/29467570/pubmed" id="29467570" target="_blank">29467570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-422308">
<a name="422308"></a>Rey E, d'Athis P, de Lauture D, Dulac O, Aicardi J, Olive G. Pharmacokinetics of carbamazepine in the neonate and in the child. <i>Int J Clin Pharmacol Biopharm</i>. 1979;Feb;17(2):90-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/422308/pubmed" id="422308" target="_blank">422308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15673889">
<a name="15673889"></a>Richard A, Girard F, Girard DC, et al, “Cisatracurium-Induced Neuromuscular Blockade is Affected by Chronic Phenytoin or Carbamazepine Treatment in Neurosurgical Patients,” <i>Anesth Analg</i>, 2005, 100(2):538-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/15673889/pubmed" id="15673889" target="_blank">15673889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7740234">
<a name="7740234"></a>Rispal P, Lasseur C, Labouyrie E, et al. Pseudolymphoma-Induced by Carbamazepine. Report of Two Cases. <i>Rev Med Interne.</i> 1995;16(3):214-218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7740234/pubmed" id="7740234" target="_blank">7740234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15955935">
<a name="15955935"></a>Rowan AJ, Ramsay RE, Collins JF, et al; VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. <i>Neurology</i>. 2005;64(11):1868-1873. doi:10.1212/01.WNL.0000167384.68207.3E<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/15955935/pubmed" id="15955935" target="_blank">15955935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.1">
<a name="Schachter.1"></a>Schachter SC. Antiseizure medications: Mechanism of action, pharmacology, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.2">
<a name="Schachter.2"></a>Schachter SC. Overview of the management of epilepsy in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 9, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8991788">
<a name="8991788"></a>Schmitz B, Trimble MR. Carbamazepine and PIP-syndrome in temporal lobe epilepsy. <i>Epilepsy Res</i>. 1995;22(3):215-220. doi:10.1016/0920-1211(95)00038-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/8991788/pubmed" id="8991788" target="_blank">8991788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28476759">
<a name="28476759"></a>Shi YW, Min FL, Zhou D, et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. <i>Neurology</i>. 2017;88(23):2183-2191. doi:10.1212/WNL.0000000000004008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/28476759/pubmed" id="28476759" target="_blank">28476759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16096883">
<a name="16096883"></a>Sierra NM, García B, Marco J, Plaza S, Hidalgo F, Bermejo T. Cross hypersensitivity syndrome between phenytoin and carbamazepine. <i>Pharm World Sci</i>. 2005;27(3):170-174. doi:10.1007/s11096-004-1736-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/16096883/pubmed" id="16096883" target="_blank">16096883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25722523">
<a name="25722523"></a>Singh H, Nanjundappa GB, Reddi SK, Chandra PS. Carbamazepine induced asterixis with hyperammonemia: a case report with review of literature. <i>Indian J Psychol Med</i>. 2015;37(1):99-101. doi:10.4103/0253-7176.150853<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/25722523/pubmed" id="25722523" target="_blank">25722523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22477826">
<a name="22477826"></a>Skalli S, Barret P, Villier C, Bussières JF. Carbamazepine-induced acute generalized exanthematous pustulosis: a case report. <i>J Pediatr Pharmacol Ther</i>. 2011;16(1):61-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/22477826/pubmed" id="22477826" target="_blank">22477826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2089834">
<a name="2089834"></a>Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. <i>DICP</i>. 1990;24(12):1214-1219. doi:10.1177/106002809002401214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/2089834/pubmed" id="2089834" target="_blank">2089834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31562941">
<a name="31562941"></a>Soria A, Bernier C, Veyrac G, Barbaud A, Puymirat E, Milpied B. Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: a retrospective study. <i>J Am Acad Dermatol</i>. 2020;82(3):606-611. doi:10.1016/j.jaad.2019.09.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/31562941/pubmed" id="31562941" target="_blank">31562941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11573664">
<a name="11573664"></a>Soriano SG, Sullivan LJ, Venkatakrishnan K, et al, “Pharmacokinetics and Pharmacodynamics of Vecuronium in Children Receiving Phenytoin or Carbamazepine for Chronic Anticonvulsant Therapy,” <i>Br J Anaesth</i>, 2001, 86(2):223-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/11573664/pubmed" id="11573664" target="_blank">11573664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15015901">
<a name="15015901"></a>Specchio LM, Beghi E. Should antiepileptic drugs be withdrawn in seizure-free patients? <i>CNS Drugs</i>. 2004;18(4):201-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/15015901/pubmed" id="15015901" target="_blank">15015901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7827672">
<a name="7827672"></a>Stafstrom CE, Nohria V, Loganbill H, et al, “Erythromycin-Induced Carbamazepine Toxicity: A Continuing Problem,” <i>Arch Pediatr Adolesc Med</i>, 1995, 149(1):99-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7827672/pubmed" id="7827672" target="_blank">7827672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29967868">
<a name="29967868"></a>Stătescu L, Constantin M, Morariu HS, Solovăstru LG. Toxic epidermal necrolysis - a case report. <i>J Crit Care Med (Targu Mures)</i>. 2017;3(1):29-33. doi:10.1515/jccm-2017-0002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/29967868/pubmed" id="29967868" target="_blank">29967868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33222552">
<a name="33222552"></a>Stephens C, Lucena MI, Andrade RJ. Genetic risk factors in the development of idiosyncratic drug-induced liver injury. <i>Expert Opin Drug Metab Toxicol</i>. 2021;17(2):153-169. doi:10.1080/17425255.2021.1854726<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/33222552/pubmed" id="33222552" target="_blank">33222552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33539847">
<a name="33539847"></a>Stephens C, Robles-Diaz M, Medina-Caliz I, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>J Hepatol</i>. 2021;75(1):86-97. doi:10.1016/j.jhep.2021.01.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/33539847/pubmed" id="33539847" target="_blank">33539847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17192163">
<a name="17192163"></a>Stoner SC, Nelson LA, Lea JW, et al. Historical review of carbamazepine for the treatment of bipolar disorder. Pharmacotherapy. 2007;27(1):68-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/17192163/pubmed" id="17192163" target="_blank">17192163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stovall.1">
<a name="Stovall.1"></a>Stovall J. Acute bipolar mania and hypomania in adults: General principles of pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 1, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25922863">
<a name="25922863"></a>Strozzi I, Nolan SJ, Sperling MR, Wingerchuk DM, Sirven J. Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. <i>Cochrane Database Syst Rev</i>. 2015;(2):CD001902.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/25922863/pubmed" id="25922863" target="_blank">25922863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15052517">
<a name="15052517"></a>Stübner S, Grohmann R, Engel R, et al. Blood dyscrasias induced by psychotropic drugs. <i>Pharmacopsychiatry</i>. 2004;37 Suppl 1:S70-S78. doi:10.1055/s-2004-815513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/15052517/pubmed" id="15052517" target="_blank">15052517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999472">
<a name="27999472"></a>Subramanian A, Adhimoolam M, Gopalakrishnan S, Rajamohammed MA. Carbamazepine-induced angioedema. <i>J Basic Clin Pharm</i>. 2016;7(4):120-122. doi:10.4103/0976-0105.189436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/27999472/pubmed" id="27999472" target="_blank">27999472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16013903">
<a name="16013903"></a>Suppes T, Dennehy EB, Hirschfeld RMA, et al, “The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,” <i>J Clin Psychiatry</i>, 2005, 66(7):870-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/16013903/pubmed" id="16013903" target="_blank">16013903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26899755">
<a name="26899755"></a>Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. <i>Am J Med</i>. 2016;129(7):753.e1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/26899755/pubmed" id="26899755" target="_blank">26899755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tegretol.1">
<a name="Tegretol.1"></a>Tegretol and Tegretol-XR (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Co.; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tegretol.2">
<a name="Tegretol.2"></a>Tegretol (carbamazepine) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9733403">
<a name="9733403"></a>Timmings PL. Sudden unexpected death in epilepsy: is carbamazepine implicated? <i>Seizure</i>. 1998;7(4):289-291. doi:10.1016/s1059-1311(98)80020-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/9733403/pubmed" id="9733403" target="_blank">9733403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7864268">
<a name="7864268"></a>Tohen M, Castillo J, Baldessarini RJ, et al. Blood Dyscrasias With Carbamazepine and Valproate: A Pharmacoepidemiological Study of 2,228 Patients at Risk. <i>Am J Psychiatry.</i> 1995;152(3):413-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/7864268/pubmed" id="7864268" target="_blank">7864268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21652013">
<a name="21652013"></a>Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. <i>Lancet Neurol</i>. 2011;10(7):609-617.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/21652013/pubmed" id="21652013" target="_blank">21652013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23360413">
<a name="23360413"></a>Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. <i>Epilepsia</i>. 2013;54(3):405-414.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/23360413/pubmed" id="23360413" target="_blank">23360413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11907855">
<a name="11907855"></a>Trent JT, Bowes LE, Romanelli P, Kerdel FA. Toxic epidermal necrolysis of the scalp following anticonvulsant use and cranial irradiation. <i>J Cutan Med Surg</i>. 2001;5(6):475-478. doi:10.1007/s10227-001-0012-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/11907855/pubmed" id="11907855" target="_blank">11907855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10752810">
<a name="10752810"></a>Tripathi M, Kaushik S. Carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. <i>Crit Care Med</i>. 2000;28(3):655-658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/10752810/pubmed" id="10752810" target="_blank">10752810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18509811">
<a name="18509811"></a>Tutor-Crespo MJ, Hermida J, Tutor JC. Relative proportions of serum carbamazepine and its pharmacologically active 10,11-epoxy derivative: effect of polytherapy and renal insufficiency. <i>Ups J Med Sci</i>. 2008;113(2):171-180. doi: 10.3109/2000-1967-225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/18509811/pubmed" id="18509811" target="_blank">18509811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22629103">
<a name="22629103"></a>Upadhyaya SK, Raina RS, Sharma A, Thawani V, Dimari D. Carbamazepine-induced erythema multiforme major in an epileptic patient with bipolar affective disorder. <i>J Pharmacol Pharmacother</i>. 2012;3(2):202-204. doi:10.4103/0976-500X.95537<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/22629103/pubmed" id="22629103" target="_blank">22629103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20888266">
<a name="20888266"></a>Wang XQ, Lang SY, Shi XB, Tian HJ, Wang RF, Yang F. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population. <i>Seizure</i>. 2010;19(9):562-566. doi:10.1016/j.seizure.2010.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/20888266/pubmed" id="20888266" target="_blank">20888266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3362374">
<a name="3362374"></a>Weaver DF, Camfield P, Fraser A. Massive carbamazepine overdose: clinical and pharmacologic observations in five episodes. <i>Neurology</i>. 1988;38(5):755-759. doi:10.1212/wnl.38.5.755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/3362374/pubmed" id="3362374" target="_blank">3362374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15119909">
<a name="15119909"></a>Weisler RH, Kalali AH, and Ketter TA, “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Extended-Release Carbamazepine Capsules as Monotherapy for Bipolar Disorder Patients With Manic or Mixed Episodes: SPD417 Study Group,” <i>J Clin Psychiatry</i>, 2004, 65(4):478-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/15119909/pubmed" id="15119909" target="_blank">15119909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9555601">
<a name="9555601"></a>Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs. <i>J Clin Psychopharmacol</i>. 1998;18(2):167-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/9555601/pubmed" id="9555601" target="_blank">9555601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10087696">
<a name="10087696"></a>Woolston JL, “Case Study: Carbamazepine Treatment of Juvenile-Onset Bipolar Disorder,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1999, 38(3):335-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/10087696/pubmed" id="10087696" target="_blank">10087696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord.</i> 2018;20(2):97-170. doi: 10.1111/bdi.12609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6132132">
<a name="6132132"></a>Yeung Laiwah AA, Rapeport WG, Thompson GG, et al. Carbamazepine-induced non-hereditary acute porphyria. <i>Lancet</i>. 1983;1(8328):790-792. doi:10.1016/s0140-6736(83)91850-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/6132132/pubmed" id="6132132" target="_blank">6132132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16081106">
<a name="16081106"></a>Zhang ZJ, Kang WH, Tan QR, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. <i>J Psychiatr Res.</i> 2007;41(3-4):360-369. doi: 10.1016/j.jpsychires.2005.06.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/abstract-text/16081106/pubmed" id="16081106" target="_blank">16081106</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13113 Version 650.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
